(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 January 2007 (04.01.2007)

PCT

(10) International Publication Number
WO 2007/000436 A1

(51) International Patent Classification:
A61K 31/4353 (2006.01) *C07D 215/36* (2006.01)
A61P 31/04 (2006.01) *C07D 215/22* (2006.01)
C07D 215/227 (2006.01)

(21) International Application Number:
PCT/EP2006/063556

(22) International Filing Date: 26 June 2006 (26.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05105769.3 28 June 2005 (28.06.2005) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOUL, Anil** [IN/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR). **MOTTE, Magali, Madeleine, Simone** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS



(Ia)



(Ib)

(57) Abstract: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof. Several of these compounds are also claimed as such. Further the combination of the above compounds with other antibacterial agents is described

WO 2007/000436 A1

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS

The present invention relates to the use of quinoline derivatives for the manufacture of a medicament for the treatment of a bacterial infection.

Resistance to first-line antibiotic agents is an emerging problem. Some important examples include penicillin-resistant *Streptococcus pneumoniae,* vancomycin-resistant enterococci, methicillin-resistant *Staphylococcus aureus,* multi-resistant salmonellae.

The consequences of resistance to antibiotic agents are severe. Infections caused by resistant microbes fail to respond to treatment, resulting in prolonged illness and greater risk of death. Treatment failures also lead to longer periods of infectivity, which increase the numbers of infected people moving in the community and thus exposing the general population to the risk of contracting a resistant strain infection. Hospitals are a critical component of the antimicrobial resistance problem worldwide. The combination of highly susceptible patients, intensive and prolonged antimicrobial use, and cross-infection has resulted in infections with highly resistant bacterial pathogens.

Self-medication with antimicrobials is another major factor contributing to resistance. Self-medicated antimicrobials may be unnecessary, are often inadequately dosed, or may not contain adequate amounts of active drug.

Patient compliance with recommended treatment is another major problem. Patients forget to take medication, interrupt their treatment when they begin to feel better, or may be unable to afford a full course, thereby creating an ideal environment for microbes to adapt rather than be killed.

Because of the emerging resistance to multiple antibiotics, physicians are confronted with infections for which there is no effective therapy. The morbidity, mortality, and financial costs of such infections impose an increasing burden for health care systems worldwide.

Therefore, there is a high need for new compounds to treat bacterial infections, especially for the treatment of infections caused by resistant strains.

WO 2004/011436 discloses substituted quinoline derivatives having activity against Mycobacteria, in particular against *Mycobacterium tuberculosis*. One particular compound of these substituted quinoline derivatives is described in Science (2005), 307, 223-227.

It has now been found that quinoline derivatives described in WO 2004/011436 also show activity against other bacteria than Mycobacteria.

Therefore, the present invention relates to the use of a compound for the manufacture of a medicament for the treatment of a bacterial infection, said compound being a compound of formula (Ia) or (Ib)



(Ia)



(Ib)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof, wherein

R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;

p is an integer equal to 1, 2, 3 or 4 ;

R^2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula  wherein Y is CH_2, O, S, NH or *N*-alkyl ;

R^3 is Ar or Het;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl or pyrimidinyl ;

R^6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or

two vicinal R^6 radicals may be taken together to form a bivalent radical of formula -CH=CH-CH=CH- ;

r is an integer equal to 1, 2, 3, 4 or 5 ;

R^7 is hydrogen, alkyl, Ar or Het ;

R^8 is hydrogen or alkyl ;

R^9 is oxo ; or

R^8 and R^9 together form the radical –CH=CH-N=;

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with hydroxy, alkyloxy or oxo;

Alk is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ;

Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl and tetrahydronaphthyl, each homocycle optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

Het is a monocyclic heterocycle selected from the group of *N*-phenoxypiperidinyl, piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl,

2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, hydroxy, alkyl, alkyloxy, and Ar-carbonyl;

halo is a substituent selected from the group of fluoro, chloro, bromo and iodo; and

haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein one or more carbon atoms are substituted with one or more halo atoms;

provided that the bacterial infection is other than a Mycobacterial infection.

The present invention also relates to a method of treating a bacterial infection in a mammal, in particular a warm-blooded mammal, more in particular a human, comprising administering an effective amount of a compound of the invention to the mammal.

The compounds according to Formula (Ia) and (Ib) are interrelated in that e.g. a compound according to Formula (Ib), with R^9 equal to oxo is the tautomeric equivalent of a compound according to Formula (Ia) with R^2 equal to hydroxy (keto-enol tautomerism).

In the framework of this application, alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with hydroxy, alkyloxy or oxo.

Preferably, alkyl is methyl, ethyl or cyclohexylmethyl, more preferably methyl or ethyl. An interesting embodiment of alkyl in all definitions used hereinbefore or hereinafter is C_{1-6}alkyl which represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms such as for example methyl, ethyl, propyl, 2-methyl-ethyl, pentyl, hexyl and the like. A preferred subgroup of C_{1-6}alkyl is C_{1-4}alkyl which represents a straight or branched saturated hydrocarbon radical having from 1 to 4 carbon atoms such as for example methyl, ethyl, propyl, 2-methyl-ethyl and the like.

In the framework of this application, Alk is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms, in particular Alk is C_{1-6}alkanediyl which represents a bivalent straight and branched chain saturated hydrocarbon radical having from 1 to 6 carbon atoms such as, for example, methylene, 1,2-ethanediyl or ethylene, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the like.

In the framework of this application, Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl. Preferably, Ar is naphthyl or phenyl, each optionally substituted with 1 or 2 substituents, each substituent independently selected from halo or alkyloxy.

In the framework of this application, Het is a monocyclic heterocycle selected from the group of *N*-phenoxypiperidinyl, piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, hydroxy, alkyl, alkyloxy and Ar-carbonyl. Preferably, Het is furanyl, piperidinyl, pyridinyl or benzo[1,3]dioxolyl or Het is thienyl, furanyl, pyridinyl or benzo[1,3]dioxolyl.

In the framework of this application, halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein one or more carbon atoms are substituted with one or more halo atoms. Preferably, halo is bromo, fluoro or chloro and preferably, haloalkyl is polyhaloC_{1-6}alkyl which is defined as mono- or polyhalosubstituted C_{1-6}alkyl, for example, methyl with one or more fluoro atoms, for

example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl and the like. In case more than one halo atom is attached to an alkyl group within the definition of haloalkyl or polyhaloC_{1-6}alkyl, they may be the same or different.

In the definition of Het, it is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises 1*H*-pyrrolyl and 2*H*-pyrrolyl.

The Ar or Het listed in the definitions of the substituents of the compounds of formula (Ia) or (Ib) (see for instance R^3) as mentioned hereinbefore or hereinafter may be attached to the remainder of the molecule of formula (Ia) or (Ib) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when Het is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.

Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.

When two vicinal R^6 radicals are taken together to form a bivalent radical of formula –CH=CH-CH=CH-, this means that the two vicinal R^6 radicals form together with the phenyl ring to which they are attached a naphthyl.

For therapeutic use, salts of the compounds of formula (Ia) or (Ib) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not, are included within the ambit of the present invention.

The pharmaceutically acceptable addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (Ia) or (Ib) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methyl-

benzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

The compounds of formula (Ia) or (Ib) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-*n*-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.
The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (Ia) or (Ib) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The *N*-oxide forms of the present compounds are meant to comprise the compounds of formula (Ia) or (Ib) wherein one or several tertiary nitrogen atoms are oxidized to the so-called *N*-oxide.

The compounds of formula (Ia) and (Ib) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones,

e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

It will be appreciated that some of the compounds of formula (I) and their *N*-oxides or addition salts may contain one or more centres of chirality and exist as stereochemically isomeric forms.

Compounds of either formula (Ia) and (Ib) and some of the intermediate compounds invariably have at least two stereogenic centers in their structure which may lead to at least 4 stereochemically different structures.

The term "stereochemically isomeric forms" as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (Ia) and (Ib), and their *N*-oxides, addition salts or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the *cis*- or *trans*-configuration. Compounds encompassing double bonds can have an E (entgegen) or Z (zusammen) -stereochemistry at said double bond. The terms cis, trans, R, S, E and Z are well known to a person skilled in the art.
Stereochemically isomeric forms of the compounds of formula (Ia) and (Ib) are obviously intended to be embraced within the scope of this invention.

Following CAS-nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an *R* or *S* descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [*R*,R**] or [*R*,S**], where *R** is always specified as the reference center and [*R*,R**] indicates centers with the same chirality and [*R*,S**] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an *S* configuration and the second center is *R*, the stereo descriptor would be specified as *S*-[*R*,S**]. If "α" and "β" are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the "α" position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric

carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated "α", if it is on the same side of the mean plane determined by the ring system, or "β", if it is on the other side of the mean plane determined by the ring system.

When a specific stereoisomeric form is indicated, this means that said form is substantially free, *i.e.* associated with less than 50 %, preferably less than 20 %, more preferably less than 10 %, even more preferably less than 5 %, further preferably less than 2 % and most preferably less than 1 % of the other isomer(s). Thus, when a compound of formula (Ia) or (Ib) is for instance specified as (αS, βR), this means that the compound is substantially free of the (αR, βS) isomer.

The compounds of either formula (Ia) and (Ib) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of either formula (Ia) and (Ib) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of either formula (Ia) and (Ib) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The tautomeric forms of the compounds of either formula (Ia) and (Ib) are meant to comprise those compounds of either formula (Ia) and (Ib) wherein e.g. an enol group is converted into a keto group (keto-enol tautomerism).

The invention also comprises derivative compounds (usually called "pro-drugs") of the pharmacologically-active compounds according to the invention, which are degraded *in vivo* to yield the compounds according to the invention. Pro-drugs are usually (but not always) of lower potency at the target receptor than the compounds to which they are degraded. Pro-drugs are particularly useful when the desired compound has chemical or physical properties that make its administration difficult or inefficient. For example,

the desired compound may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further discussion on pro-drugs may be found in Stella, V. J. *et al.*, "Prodrugs", *Drug Delivery Systems*, 1985, pp. 112-176, and *Drugs,* 1985, 29, pp. 455-473.

Pro-drugs forms of the pharmacologically-active compounds according to the invention will generally be compounds according to either Formula (Ia) and (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, having an acid group which is esterified or amidated. Included in such esterified acid groups are groups of the formula $-COOR^x$, where R^x is a C_{1-6}alkyl, phenyl, benzyl or one of the following groups :



Amidated groups include groups of the formula $-CONR^yR^z$, wherein R^y is H, C_{1-6}alkyl, phenyl or benzyl and R^z is –OH, H, C_{1-6}alkyl, phenyl or benzyl.

Compounds according to the invention having an amino group may be derivatised with a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base will hydrolyze with first order kinetics in aqueous solution.

Whenever used herein, the term "compounds of formula (Ia) or (Ib)" is meant to also include their pharmaceutically acceptable acid or base addition salts, their *N*-oxide forms, their tautomeric forms or their stereochemically isomeric forms. Of special interest are those compounds of formula (Ia) or (Ib) which are stereochemically pure.

A first interesting embodiment of the present invention relates to a compound of formula (Ia) or (Ib) wherein Alk represent methylene or ethylene, in particular ethylene.

A second interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein

R^1 is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy ;

p is an integer equal to 1, 2, 3 or 4 ; in particular 1 or 2;

R^2 is hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylthio or a radical of formula  wherein Y is O ;

R^3 is Ar or Het ;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl;

R^6 is hydrogen, halo or alkyl ; or

two vicinal R^6 radicals may be taken together to form a bivalent radical of formula -CH=CH-CH=CH- ;

r is an integer equal to 1 ;

R^7 is hydrogen ;

R^8 is hydrogen or alkyl ;

R^9 is oxo ; or

R^8 and R^9 together form the radical –CH=CH-N=;

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with hydroxy ;

Alk is ethylene;

Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl and tetrahydronaphthyl, each homocycle optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, haloalkyl, cyano, alkyloxy and morpholinyl ;

Het is a monocyclic heterocycle selected from the group of *N*-phenoxypiperidinyl, piperidinyl, furanyl, thienyl, pyridinyl and pyrimidinyl ; or a bicyclic heterocycle selected from the group of benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from alkyl or Ar-carbonyl; and

halo is a substituent selected from the group of fluoro, chloro and bromo.

haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated

hydrocarbon radical having from 1 to 6 carbon atoms; wherein one or more carbon atoms are substituted with one or more halo atoms.

A third interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^1 is hydrogen, halo, alkyl, alkyloxy, Ar or Het; preferably, R^1 is hydrogen, halo, alkyl or alkyloxy; more preferably, R^1 is hydrogen or halo; most preferred R^1 is halo, e.g. bromo or chloro, in particular bromo.

A fourth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein p is equal to 1 or 2; preferably p is equal to 1; more preferably p is equal to 1 and R^1 is other than hydrogen.

A fifth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein p is equal to 1 and said R^1 substituent is placed in position 5, 6 or 7 of the quinoline ring; preferably in position 6.

A sixth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^2 is hydrogen, alkyloxy, alkylthio, alkyloxyalkyloxy or mono or di(alkyl)amino; preferably, R^2 is hydrogen, alkyloxy or alkylthio; more preferably, R^2 is alkyloxy or alkylthio; most preferably, R^2 is alkyloxy, in particular C_{1-4}alkyloxy; more in particular methyloxy.

A seventh interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^3 is Ar, optionally substituted with 1 or 2 substituents, said substituent preferably being a halo, haloalkyl, alkyloxy, haloalkyloxy or alkyl; more preferably said substituent being a halo, haloalkyl or alkyloxy; even more preferably said substituent being a halo or alkyloxy; most preferably said substituent being a halo; preferably, Ar in the definition of R^3 is naphthyl or phenyl, optionally substituted with 1 or 2 halo atoms, in particular 4-halophenyl; more preferably, R^3 is naphthyl or phenyl; most preferred R^3 is 1-naphthyl or phenyl.

Another interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^3 is Het, in particular benzo[1,3]dioxolyl.

An eighth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^4 and R^5 each independently are hydrogen, alkyl or benzyl; preferably hydrogen or alkyl, in particular hydrogen or C_{1-4}alkyl; more preferably C_{1-4}alkyl; most preferably methyl.

A ninth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^4 and R^5 together and including the N to which they are attached form a radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl or pyrimidinyl; preferably R^4 and R^5 together and including the N to which they are attached form a radical selected from the group of pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl or pyrimidinyl; more preferably R^4 and R^5 together and including the N to which they are attached form a radical selected from the group of piperidinyl or morpholinyl, in particular a piperidinyl.

A tenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^6 is hydrogen, alkyl, alkyloxy or halo; preferably, R^6 is hydrogen.

An eleventh interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein r is 1 or 2; preferably r is 1.

A twelfth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R^7 is hydrogen or methyl; preferably R^7 is hydrogen.

A thirteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein, for compounds according to Formula (Ib) only, R^8 is hydrogen or alkyl; and R^9 is oxo ; preferably R^8 is alkyl, preferably methyl, and R^9 is oxo.

A fourteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein the compound is a compound according to formula (Ia).

A fifteenth interesting embodiment relates to a compound of formula (Ia) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein one or more, preferably all, of the following definitions apply :
R^1 is hydrogen, halo, alkyl, alkyloxy, Ar or Het; in particular hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkyloxy, Ar or Het; more in particular hydrogen, bromo, methyl, methyloxy, hydroxymethyl, phenyl, pyridinyl, thienyl or furanyl;
p = 1 or 2; in particular 1;
R^2 is alkyloxy, alkylthio, mono-or di(alkyl)amino, alkyloxyalkyloxy; in particular C_{1-4}alkyloxy, C_{1-4}alkylthio, mono-or di(C_{1-4}alkyl)amino, C_{1-4}alkyloxyC_{1-4}alkyloxyC_{1-4}alkyloxy; more in particular C_{1-4}alkyloxy, such as methyloxy;
R^3 is naphthyl, phenyl, each of said ring systems being optionally substituted; in particular phenyl, optionally substituted with 1 or 2 substituents selected from halo, haloalkyl, alkyloxy, haloalkyloxy or alkyl; or naphthyl; more in particular phenyl, optionally substituted with 1 or 2 substituents selected from halo, haloC_{1-4}alkyl, C_{1-4}alkyloxy, haloC_{1-4}alkyloxy or C_{1-4}alkyl; or naphthyl;
R^4 and R^5 each independently are hydrogen or alkyl; in particular hydrogen or C_{1-4}alkyl; more in particular hydrogen or methyl; or R^4 and R^5 together and including the N to which they are attached form a piperidinyl;
R^6 is hydrogen, halo, alkyl or alkyloxy; in particular hydrogen, halo, C_{1-4}alkyl or C_{1-4}alkyloxy;
r is equal to 1;
R^7 is hydrogen;
Alk is methylene or ethylene.

A sixteenth interesting embodiment is the use of a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the

manufacture of a medicament for the treatment of an infection with a gram-positive and/or a gram-negative bacterium.

A seventeenth interesting embodiment is the use of a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the manufacture of a medicament for the treatment of an infection with a gram-positive bacterium.

A eighteenth interesting embodiment is the use of the compounds of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the manufacture of a medicament for the treatment of an infection with a gram-negative bacterium.

A nineteenth interesting embodiment is the use of a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the manufacture of a medicament for the treatment of a bacterial infection wherein the compound of formula (Ia) or (Ib) has a $IC_{90} < 15$ μl/ml against at least one bacterium, in particular a gram-positive bacterium; preferably a $IC_{90} < 10$ μl/ml; more preferably a $IC_{90} < 5$ μl/ml; the IC_{90} value being determined as described hereinafter.

Preferably, in the compounds of formula (Ia) and (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment, the term "alkyl" represents C_{1-6}alkyl, more preferably C_{1-4}alkyl.

Preferred compounds are selected from the following compounds :



a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

Especially preferred compounds are selected from compound 14, 15, 7, 8, 9, 20, 39, 37, 38, 55 and 40 (see Tables hereinbelow), a *N*-oxide thereof, a tautomeric form thereof or a stereochemically isomeric form thereof; in particular preferred compounds are compounds 39, 37, 38, 55 and 40, a *N*-oxide thereof, a tautomeric form thereof or a stereochemically isomeric form thereof.

The present invention also relates to any one compound out of Tables 1 to 5 hereinbelow.

In particular, the present invention relates to a compound selected from



R^1_a	R^1_b	R^1_c	R^3	X
H	H	H	phenyl	O
H	CH_3	H	phenyl	O
H	OCH_3	H	phenyl	O
H	Br	H	phenyl	S
H	Br	H	1-naphthyl	O
H	Br	CH_3	phenyl	O
H	Cl	H	phenyl	O
Br	H	H	phenyl	O

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

The present invention also relates to a compound selected from



R^1	R^3	R^4
Br	4-fluorophenyl	H
H	4-fluorophenyl	H
Br	4-chlorophenyl	CH_3

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

The present invention also relates to a compound selected from



R^1	R^3	R^4	stereochemistry
Br	4-fluorophenyl	H	(A)
Br	4-fluorophenyl	H	(B)
H	4-fluorophenyl	H	(A)
H	4-fluorophenyl	H	(B)
Br	4-chlorophenyl	CH_3	(B)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

Preferably, the compound of formula (Ia) or (Ib) is a particular diastereoisomer (substantially free of the other diastereoisomer(s)). In case the compound of formula (Ia) or (Ib) has two chiral centers this means that the compound is a racemic mixture of the (R,S) and (S,R) enantiomers or a racemic mixture of the (R,R) and (S,S) enantiomer. Hereinafter, the racemic mixtures of 2 enantiomers are indicated as diastereoisomer A or B. Whether the racemic mixture is indicated as A or B depends on whether it is first isolated in the synthesis protocol (i.e. A) or second (i.e. B). More preferably, the compound of formula (Ia) or (Ib) is a particular enantiomer (substantially free of the other enantiomers). In case the compound of formula (Ia) or (Ib) has two chiral centers this means that the compound is the (R,S), (S,R), (R,R) or (S,S) enantiomer. Hereinafter, said particular enantiomers are indicated as A1, A2, B1 or B2. Whether the enantiomer is indicated as A1, A2, B1 or B2 depends on whether it is isolated first or second in the synthesis protocol.

The compounds of formula (Ia) or (Ib) can be prepared according to the methods described in WO 2004/011436, which is incorporated herein by reference.
In general, the compounds according to the invention can be prepared by a succession of steps, each of which is known to the skilled person.

In particular, the compounds according to formula (Ia) can be prepared by reacting an intermediate compound of formula (II) with an intermediate compound of formula (III) according to the following reaction scheme (1) :

Scheme 1



(II) (III)

using nBuLi in a mixture of diisopropyl amine and tetrahydrofuran, wherein all variables are defined as in formula (Ia). Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between –20 and –70 °C.
The same reaction procedure can be used to synthesize compounds of formula (Ib).

The starting materials and the intermediate compounds of formula (II) and (III) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediate compounds of formula (II-a) or (II-b) may be prepared according to the following reaction scheme (2):

Scheme 2



wherein all variables are defined as in formula (Ia). Reaction scheme (2) comprises step (a) in which an appropriately substituted aniline is reacted with an appropriate acylchloride such as 3-phenylpropionyl chloride, 3-fluorobenzenepropionyl chloride or *p*-chlorobenzenepropionyl chloride, in the presence of a suitable base, such as triethylamine and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (b) the adduct obtained in step (a) is reacted with phosphoryl chloride ($POCl_3$) in the presence of *N*,*N*-dimethylformamide (Vilsmeier-Haack formylation followed by cyclization). The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (c-1), a specific R^2-group, wherein R^2 is for example a C_{1-6}alkyloxy radical is introduced by reacting the intermediate compound obtained in step (b) with $^-O\text{-}C_{1-6}$alkyl in the presence of a suitable solvent, such as for example HO-C_{1-6}alkyl. The intermediate compound obtained in step (b)

can also be converted into an intermediate compound wherein R^2 is for example a C_{1-6}alkylthio radical by reaction with $S=C(NH_2)_2$ in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol (step (c-2)) followed by reaction with C_{1-6}alkyl-I in the presence of a suitable base, such as for example K_2CO_3 and a suitable solvent, such as for example 2-propanone. The intermediate compound obtained in step (b) can also be converted into an intermediate compound wherein R^2 is $N(R^{2a})$(alkyl) wherein R^{2a} is hydrogen or alkyl, by reaction with a suitable salt of $NH(R^{2a})$(alkyl) in the presence of a suitable base, such as for example potassium carbonate, and a suitable solvent, such as for example acetonitrile (step (c-3)). The intermediate compound obtained in step (b) can also be converted into an intermediate compound wherein R^2 is alkyloxyalkyloxy optionally substituted with alkyloxy, said R^2 being represented by R^{2b}, by reaction with alkyloxyalkylOH optionally substituted with alkyloxy in the presence of NaH and a suitable solvent, such as for example tetrahydrofuran (step (C-4)).

Intermediate compounds according to formula (II-e) may be prepared according to the following reaction scheme (3), wherein in a first step (a) a substituted indole-2,3-dione is reacted with an optionally substituted 3-phenylpropionaldehyde in the presence of a suitable base such as sodium hydroxide (Pfitzinger reaction), after which the carboxylic acid compound is decarboxylated in a next step (b) at high temperature in the presence of a suitable reaction-inert solvent such as diphenylether.

Scheme 3



(II-e)

It is evident that in the foregoing and in the following reactions, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art, such as extraction, crystallization and chromatography. It is further evident that reaction products that exist in more than one enantiomeric form, may be isolated from their mixture by known techniques, in particular preparative chromatography, such as preparative HPLC, chiral chromatography. Individual diastereoisomers or individual enantiomers can also be obtained by Supercritical Fluid Chromatography (SCF).

The intermediate compounds of formula (III) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediate compounds of formula (III) may be prepared according to the following reaction scheme (4):

Scheme 4



(III)

Reaction scheme (4) comprises step (a) in which for instance a suitable acid is reacted with $NH(CH_3)(OCH_3)$ in the presence of 1,1'-carbonyldiimidazole and a suitable solvent, such as for example CH_2Cl_2. In a next step (b), the product obtained in step (a) is reacted with Grignard reagens (CH_3MgCl) in the presence of a suitable solvent, such as for example tetrahydrofuran. In a next step (c), an amino group ($-NR^4R^5$) is introduced by reacting the intermediate compound obtained in step (b) with a primary or secondary amine HNR^4R^5 in the presence of $CH_2(=O)$, a suitable acid, such as for example hydrochloric acid and the like, and a suitable solvent, such as for example an alcohol, e.g. ethanol.

Intermediate compounds of formula (III) wherein Alk represents ethylene, said intermediates being represented by formula (III-a), can alternatively be prepared according to the following reaction scheme (5):

Scheme 5



(III-a)

Reaction scheme 5 comprises step (a) wherein a suitable aldehyde is reacted with acetone in the presence of a suitable base, such as for example sodium hydroxide. In a next step (b), the product obtained in step (a) is reacted with a primary or secondary amine HNR^4R^5 in the presence of $CH_2(=O)$, a suitable acid, such as for example hydrochloric acid and the like, and a suitable solvent, such as for example an alcohol, e.g. ethanol. In a next step (c), the product obtained in step (b) is hydrogenated (H_2) in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example water and an alcohol, e.g. ethanol.

The compounds of formula (Ia) or (Ib) can also be converted into each other following art-known functional group transformation reactions, comprising the one described hereinafter.

For instance, compounds of formula (Ia) or (Ib) wherein R^1 is halo, in particular bromo, can be converted into a compound of formula (Ia) or (Ib) wherein R^1 is hydrogen, by reaction with $HCOONH_4$ in the presence of a suitable catalyst such as for example palladium on charcoal, and in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol. The same reaction conditions can be used to convert a compound of formula (Ia) or (Ib) wherein R^4 is benzyl into a compound of formula (Ia) or (Ib) wherein R^4 is hydrogen.

Compounds of formula (Ia) or (Ib) wherein R^1 is halo, in particular bromo, can also be converted into a compound of formula (Ia) or (Ib) wherein R^1 is Het, in particular pyridine, by reaction with a suitable boronic acid derivative of Het, e.g. pyridine-3-boronic acid, in the presence of a suitable catalyst, such as for example (triphenylphosphine)palladium(0), in the presence of a suitable solvent, such as for example ethyleneglycol dimethylether, and a suitable base, such as for example sodium carbonate.

Compounds of formula (Ia) or (Ib) wherein R^1 is halo, in particular bromo, can also be converted into an intermediate wherein R^1 is formyl by reaction with *N*,*N*-dimethylformamide in the presence of *n*BuLi and a suitable solvent, such as for example tetrahydrofuran. These intermediates can then be converted into a compound

of formula (Ia) or (Ib) wherein R^1 is $-CH_2$-OH by reaction with a suitable reducing agent, such as for example $NaBH_4$ and in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol, and tetrahydrofuran.

As indicated above, the compounds of formula (Ia) and (Ib) can be used as antibacterials.
In general, bacterial pathogens may be classified as either gram-positive or gram-negative pathogens. Antibiotic compounds with activity against both gram-positive and gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as active against gram-positive and/or gram-negative bacterial pathogens. In particular, the present compounds are active against at least one gram-positive bacterium, preferably against several gram-positive bacteria, more preferably against one or more gram-positive bacteria and/or one or more gram-negative bacteria.

The present compounds have bactericidal or bacteriostatic activity.

Examples of gram-positive and gram-negative aerobic and anaerobic bacteria, include Staphylococci, for example *S. aureus*; Enterococci, for example *E. faecalis*; Streptococci, for example *S. pneumoniae*, *S. mutans*, *S. pyogens*; Bacilli, for example *Bacillus subtilis*; Listeria, for example *Listeria monocytogenes*; Haemophilus, for example *H. influenza*; Moraxella, for example *M. catarrhalis*; Pseudomonas, for example *Pseudomonas aeruginosa*; and Escherichia, for example *E. coli*.
Gram-positive pathogens, for example Staphylococci, Enterococci and Streptococci are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from for example a hospital environment once established. Examples of such strains are methicillin resistant *Staphylococcus aureus* (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant *Streptococcus pneumoniae* and multiple resistant *Enterococcus faecium*.

The compounds of the present invention also show activity against resistant bacterial strains.

The compounds of the present invention are especially active against *Streptococcus pneumoniae* and/or *Staphylococcus aureus*, including resistant *Staphylococcus aureus* such as for example methicillin resistant *Staphylococcus aureus* (MRSA), especially against *Staphylococcus aureus*, including resistant *Staphylococcus aureus*. The present

compounds have especially a good activity against SPN 6305 (*Streptococcus pneumoniae* (ATCC6305)) and/or STA 29213 (*Staphylococcus aureus* (ATCC29213)).

In particular, the compounds of the present invention are active on those bacteria of which the viability depends on proper functioning of F1F0 ATP synthase. Without being bound to any theory, it is taught that the activity of the present compounds lies in inhibition of the F1F0 ATP synthase, in particular the inhibition of the F0 complex of the F1F0 ATP synthase, more in particular the inhibition of subunit c of the F0 complex of the F1F0 ATP synthase, leading to killing of the bacteria by depletion of the cellular ATP levels of the bacteria.

Whenever used hereinbefore or hereinafter, that the compounds can treat a bacterial infection it is meant that the compounds can treat an infection with one or more bacterial strains.
Whenever used hereinbefore or hereinafter, that the bacterial infection is other than a Mycobacterial infection it is meant that the bacterial infection is other than an infection with one or more Mycobacteria strains.

The compounds of the present invention have an acceptable $t_{1/2}$, i.e. The half-life ($t_{1/2}$) of a compound refers to the time course necessary for the quantity of the compound in the body (or plasma concentration) to be reduced to half of its original level through various elimination processes.

The exact dosage and frequency of administration of the present compounds depends on the particular compound of formula (Ia) or (Ib) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

The compound of the present invention may be administered in a pharmaceutically acceptable form optionally in a pharmaceutically acceptable carrier. The compounds and compositions comprising the compounds can be administered by routes such as

topically, locally or systemically. Systemic application includes any method of introducing the compound into the tissues of the body, e.g., intrathecal, epidural, intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous, sublingual, rectal, and oral administration. The specific dosage of antibacterial to be administered, as well as the duration of treatment, may be adjusted as needed.

Bacterial infections which may be treated by the present compounds include, for example, central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients.

Given the fact that the compounds of formula (Ia) or (Ib) are active against bacterial infections, the present compounds may be combined with other antibacterial agents in order to effectively combat bacterial infections.

Therefore, the present invention also relates to a combination of (a) a compound of formula (Ia) or (Ib), and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents.

The present invention also relates to a combination of (a) a compound of formula (Ia) or (Ib), and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents, for use as a medicine.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of (a) a compound of formula (Ia) or (Ib), and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents, is also comprised by the present invention.

The present invention also relates to the use of a combination or pharmaceutical composition as defined above for the treatment of a bacterial infection.

The present pharmaceutical composition may have various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compounds, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral unit dosage forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight of the active ingredients, and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total composition.

The weight to weight ratio's of the compound of formula (Ia) or (Ib) and (b) the other antibacterial agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound of formula (Ia) or (Ib) and the other antibacterial agent(s) used, the particular condition being treated, the severity of the condition being

treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

The compounds of formula (Ia) or (Ib) and the one or more other antibacterial agents may be combined in a single preparation or they may be formulated in separate preparations so that they can be administered simultaneously, separately or sequentially. Thus, the present invention also relates to a product or kit containing (a) a compound of formula (Ia) or (Ib), and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of a bacterial infection.

The pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof. The daily dosage of the compound according to the invention will, of course, vary with the compound employed, the mode of administration, the treatment desired and the bacterial disease indicated.

The other antibacterial agents which may be combined with the compounds of formula (Ia) or (Ib) are antibacterial agents known in the art. The other antibacterial agents comprise antibiotics of the β-lactam group such as natural penicillins, semisynthetic penicillins, natural cephalosporins, semisynthetic cephalosporins, cephamycins,

1-oxacephems, clavulanic acids, penems, carbapenems, nocardicins, monobactams; tetracyclines, anhydrotetracyclines, anthracyclines; aminoglycosides; nucleosides such as *N*-nucleosides, C-nucleosides, carbocyclic nucleosides, blasticidin S; macrolides such as 12-membered ring macrolides, 14-membered ring macrolides, 16-membered ring macrolides; ansamycins; peptides such as bleomycins, gramicidins, polymyxins, bacitracins, large ring peptide antibiotics containing lactone linkages, actinomycins, amphomycin, capreomycin, distamycin, enduracidins, mikamycin, neocarzinostatin, stendomycin, viomycin, virginiamycin; cycloheximide; cycloserine; variotin; sarkomycin A; novobiocin; griseofulvin; chloramphenicol; mitomycins; fumagillin; monensins; pyrrolnitrin; fosfomycin; fusidic acid; D-(*p*-hydroxyphenyl)glycine; D-phenylglycine; enediynes.

Specific antibiotics which may be combined with the present compounds of formula (Ia) or (Ib) are for example benzylpenicillin (potassium, procaine, benzathine), phenoxymethylpenicillin (potassium), phenethicillin potassium, propicillin, carbenicillin (disodium, phenyl sodium, indanyl sodium), sulbenicillin, ticarcillin disodium, methicillin sodium, oxacillin sodium, cloxacillin sodium, dicloxacillin, flucloxacillin, ampicillin, mezlocillin, piperacillin sodium, amoxicillin, ciclacillin, hectacillin, sulbactam sodium, talampicillin hydrochloride, bacampicillin hydrochloride, pivmecillinam, cephalexin, cefaclor, cephaloglycin, cefadroxil, cephradine, cefroxadine, cephapirin sodium, cephalothin sodium, cephacetrile sodium, cefsulodin sodium, cephaloridine, cefatrizine, cefoperazone sodium, cefamandole, vefotiam hydrochloride, cefazolin sodium, ceftizoxime sodium, cefotaxime sodium, cefmenoxime hydrochloride, cefuroxime, ceftriaxone sodium, ceftazidime, cefoxitin, cefmetazole, cefotetan, latamoxef, clavulanic acid, imipenem, aztreonam, tetracycline, chlortetracycline hydrochloride, demethylchlortetracycline, oxytetracycline, methacycline, doxycycline, rolitetracycline, minocycline, daunorubicin hydrochloride, doxorubicin, aclarubicin, kanamycin sulfate, bekanamycin, tobramycin, gentamycin sulfate, dibekacin, amikacin, micronomicin, ribostamycin, neomycin sulfate, paromomycin sulfate, streptomycin sulfate, dihydrostreptomycin, destomycin A, hygromycin B, apramycin, sisomicin, netilmicin sulfate, spectinomycin hydrochloride, astromicin sulfate, validamycin, kasugamycin, polyoxin, blasticidin S, erythromycin, erythromycin estolate, oleandomycin phosphate, tracetyloleandomycin, kitasamycin, josamycin, spiramycin, tylosin, ivermectin, midecamycin, bleomycin sulfate, peplomycin sulfate, gramicidin S, polymyxin B, bacitracin, colistin sulfate, colistinmethanesulfonate sodium, enramycin, mikamycin, virginiamycin, capreomycin sulfate, viomycin, enviomycin, vancomycin, actinomycin D, neocarzinostatin, bestatin, pepstatin, monensin, lasalocid, salinomycin, amphotericin B, nystatin, natamycin,

trichomycin, mithramycin, lincomycin, clindamycin, clindamycin palmitate hydrochloride, flavophospholipol, cycloserine, pecilocin, griseofulvin, chloramphenicol, chloramphenicol palmitate, mitomycin C, pyrrolnitrin, fosfomycin, fusidic acid, bicozamycin, tiamulin, siccanin.

EXPERIMENTAL PART

Of some compounds the absolute stereochemical configuration of the stereogenic carbon atom(s) therein was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" isomeric forms can be unambiguously characterized by a person skilled in the art, using art-known methods such as, for example, X-ray diffraction.

In case "A" and "B" are stereoisomeric mixtures, in particular mixtures of diastereoisomers, they can be further separated whereby the respective first fractions isolated are designated "A1" respectively "B1" and the second as "A2" respectively "B2", without further reference to the actual stereochemical configuration. However, said "A1", "A2" and "B1", "B2" isomeric forms, in particular said "A1", "A2" and "B1", "B2"enantiomeric forms, can be unambiguously characterized by a person skilled in the art, using art-known methods such as, for example, X-ray diffraction.

Hereinafter, "THF" is defined as tetrahydrofuran, "DMF" is defined as *N*,*N*-dimethylformamide, "DIPE" is defined as diisopropyl ether and "CDI" is defined as 1,1'-carbonyldiimidazole.

A. Preparation of the intermediate compounds

Example A1

a) Preparation of intermediate 1



$POCl_3$ (327 ml) was added slowly at 5°C to DMF (120 ml). After complete addition, *N*-(4-methylphenyl)benzenepropanamide (0.501 mol) was added. The mixture was stirred at 80°C overnight, then brought to room temperature and poured out on ice. EtOAc was added. The mixture was stirred for 1 hour, while ice was added and then extracted with EtOAc. The organic layer was separated, washed with H_2O, dried ($MgSO_4$), filtered and the solvent was evaporated. Yield: 182.2 g of intermediate 1.

b) Preparation of intermediate 2



A mixture of intermediate 1 (0.5 mol) in CH_3ONa (30 %) (300 ml) and CH_3OH (300 ml) was stirred at 70°C for 48 hours. The mixture was brought to room temperature, poured out on ice and extracted with CH_2Cl_2. The organic layer was separated, washed with H_2O, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (120 g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2/cyclohexane 30/70; 20-45 µm). The pure fractions were collected and the solvent was evaporated. Yield: 64 g of intermediate 2.

Example A2

a) Preparation of intermediate 3



$POCl_3$ (2.74 mol) was added dropwise at 5°C/10°C to DMF (94 ml). *N*-(4-methoxyphenyl)benzenepropanamide (0.38 mol) was added. The mixture was stirred at 80°C overnight, then brought to room temperature and poured out on ice. The precipitate was filtered off, washed with H_2O and dried in vacuo. Yield: 41.5 g of intermediate 3 (37 %).

b) Preparation of intermediate 4



A mixture of intermediate 3 (0.14 mol) in CH_3ONa 30 % (90 ml) and CH_3OH (400 ml) was stirred and refluxed overnight. The mixture was brought to room temperature, poured out on ice and extracted with EtOAc. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (38 g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2/cyclohexane 65/35; 35-70 µm). The pure fractions were collected and the solvent was evaporated. Yield: 30 g of intermediate 4 (73 %).

Example A3

a) Preparation of intermediate 5



Benzenepropanoyl chloride (0.67 mol) was added dropwise at 5°C to a mixture of 3-bromobenzenamine (0.58 mol) and Et_3N (0.72 mol) in CH_2Cl_2 (1000 ml). The mixture was stirred at room temperature for 4 hours, poured out into ice water and NH_4OH. The organic layer was washed with HCl 1N, then with K_2CO_3 10 %, dried ($MgSO_4$), filtered, and the solvent was evaporated till dryness. Yield: 190 g of intermediate 5.

b) Preparation of intermediate 6 and 7



intermediate 6



intermediate 7

$POCl_3$ (2.3 mol) was added dropwise at 5°C to DMF (0.98 mol). The mixture was brought to room temperature. Intermediate 5 (0.33 mol) was added. The mixture was stirred at 85°C for 6 hours, then cooled to room temperature, poured out into ice water. CH_2Cl_2 was added. Both layers were stirred for 2 hours. The mixture was extracted with CH_2Cl_2. The organic layer was washed with K_2CO_3 10 %, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (84g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2/cyclohexane 30/70; 20-45 µm). The desired fractions were collected and the solvent was evaporated. Yield: 34.1g (31 %) of intermediate 6 and 9g (8 %) of intermediate 7.

c. Preparation of intermediate 8



A mixture of intermediate 6 (0.1 mol) and $NaOCH_3$ (0.53 mol) in methanol (340 ml) was stirred and refluxed for 20 hours, then cooled to room temperature, poured out into ice water and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. Yield: 79 % of intermediate 8 (melting point: 100°C).

Example A4

a. Preparation of intermediate 9



Benzenepropanoylchloride (0.488 mol) was added dropwise at room temperature to a solution of 4-bromobenzenamine (0.407 mol) in Et_3N (70 ml) and CH_2Cl_2 (700 ml) and the mixture was stirred at room temperature overnight. The mixture was poured out into water and concentrated NH_4OH, and extracted with CH_2Cl_2 . The organic layer was dried ($MgSO_4$), filtered, and the solvent was evaporated . The residue was crystallized from diethyl ether . The residue (119.67 g) was taken up in CH_2Cl_2 and washed with HCl 1N . The organic layer was dried ($MgSO_4$), filtered, and the solvent was evaporated. Yield: 107.67 g of intermediate 9 .

b. Preparation of intermediate 10



The reaction was carried out twice . $POCl_3$ (1.225 mol) was added dropwise at 10°C to DMF (0.525 mol) . Then intermediate 9 (0.175 mol) was added at room temperature . The mixture was stirred overnight at 80°C, poured out on ice and extracted with CH_2Cl_2 . The organic layer was dried ($MgSO_4$), filtered, and the solvent was evaporated . Yield: 77.62 g of intermediate 10 (67 %).

c. Preparation of intermediate 11



A mixture of intermediate 10 (0.233 mol) in CH_3ONa (30 %) in methanol (222.32 ml) and methanol (776 ml) was stirred and refluxed overnight, then poured out on ice and extracted with CH_2Cl_2 . The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated . The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2/cyclohexane 20/80 and then 100/0; 20-45 µm). The pure fractions were collected and the solvent was evaporated . Yield: 25 g of intermediate 11 (33 %) (melting point: 84°C).

Example A5

a. Preparation of intermediate 12



Benzenepropanoyl chloride (0.17 mol) was added dropwise at 5 °C to a mixture of 4-bromo-3-methylbenzenamine (0.13 mol) and Et_3N (0.18 mol) in CH_2Cl_2 (250 ml). The mixture was brought to room temperature, stirred for 16 hours, poured out into ice water and NH_4OH 30 % and extracted with CH_2Cl_2. The organic layer was washed with HCl 1N, H_2O and K_2CO_3 10 %, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was taken up in diethyl ether. The precipitate was filtered off and dried. Yield: 39 g of intermediate 12 (91 %).

b. Preparation of intermediate 13



$POCl_3$ (0.8 mol) was added dropwise at 5°C to DMF (0.34 mol). The mixture was brought to room temperature. Intermediate 12 (0.11 mol) was added. The mixture was stirred at 85°C for 7 hours, then cooled to room temperature, poured out into ice water and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated till dryness. The residue was crystallized from *i*PrOH. The precipitate was filtered, washed with iPrOH and dried. Yield: 13.9 g of intermediate 13 (35 %).

c. Preparation of intermediate 14



A mixture of intermediate 13 (0.04 mol) and CH_3ONa (0.2 mol) in CH_3OH (140 ml) was stirred and refluxed for 16 hours, then cooled to room temperautre, poured out into ice water and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. Yield: 13.5 g of intermediate 14 (98 %).

Example A6A

a. Preparation of intermediate 15



A mixture of intermediate 10 (prepared according to A4.b) (0.045 mol) and thiourea (0.05 mol) in ethanol (150 ml) was stirred and refluxed for 8 hours and then brought to

room temperature. A solution of KOH (0.068 mol) in H_2O (15 ml) was added. The mixture was stirred and refluxed for 1 hour and poured out on ice. The precipitate was filtered off, washed with H_2O and dried. Yield: 11 g of intermediate 15 (74 %).

b. Preparation of intermediate 16



CH_3I (0.037 mol) was added slowly at room temperature to a mixture of intermediate 15 (0.033 mol) and K_2CO_3 (0.037 mol) in 2-propanone (150 ml). The mixture was stirred at room temperature for 8 hours, poured out into H_2O and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. Yield: 11.2 g (97 %). Part of this fraction (2 g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 1.45 g of intermediate 16 (70 %).

Example A6B

a. Preparation of intermediate 17



A solution of intermediate 1 (8 g, 0.03 mol) and thiourea (2.5 g, 0.033 mol) in ethanol (100 ml) was stirred at 80°C for 4 hours and was then cooled to room temperature. A solution of potassium hydroxide (2.5 g, 0.045 mol) in water (10 ml) was added and the mixture was heated for 1 hour at 80°C and was then cooled to room temperature and poured out into water. The precipitate was filtered off, washed with water and dried. Yield: 7.6 g of intermediate 17 (95 %).

b. Preparation of intermediate 18



A solution of intermediate 17 (7.6 g, 0.029 mol), methyliodide (1.9 ml, 0.031 mol), and potassium carbonate (4.3 g, 0.031 mol) in acetone (170 ml) was stirred for 4 hours at room temperature, poured into water and extracted with CH_2Cl_2. The organic layer was washed with water, dried over $MgSO_4$, filtered and the solvent was evaporated. The residue was crystallized from ethylic ether. The precipitate was filtered off and dried. Yield: 5.83 g of intermediate 18 (73%) (melting point: 82°C).



Intermediate 19 was prepared from intermediate 20



(prepared according to Example A2 in WO2004/011436 starting from 3-(4-chlorophenyl) propionic acid;yield: 88 g of intermediate 20 (70.7 %)) following the same procedure as outlined above in Example A6A and A6B. Yield: 94% of intermediate 19.

Example A7

a. Preparation of intermediate 21



$POCl_3$ (3.234 mol) was added slowly at 5°C to DMF (111 ml). After complete addition, *N*-(4-chlorophenyl)benzenepropanamide (0.462 mol) was added. The mixture was stirred at 80°C overnight, then brought to room temperature and poured out on ice. EtOAc was added. The mixture was stirred for 1 hour while ice was added and then extracted with EtOAc. The organic layer was separated, washed with H_2O, dried ($MgSO_4$), filtered and the solvent was evaporated. Yield: 129 g of intermediate 21 (97 %).

b Preparation of intermediate 22



A mixture of intermediate 21 (0.447 mol) in CH_3ONa 30 % (300 ml) and CH_3OH (300 ml) was stirred at 80°C overnight. The mixture was brought to room temperature, poured out on ice and extracted with CH_2Cl_2. The organic layer was separated, washed with H_2O, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (82 g) was purified by column chromatography over silica gel (eluent: cyclohexane/CH_2Cl_2 70/30; 20-45 µm). The pure fractions were collected and the solvent was evaporated. Yield: 45 g of intermediate 22 (35 %).

Example A8

a. Preparation of intermediate 23



A solution of intermediate 20 (1.5 g, 0.00409 mol), dimethylamine hydrochloride (1.33 g, 0.001636 mol), potassium carbonate (2.83 g, 0.002045 mol) in acetonitrile (15 ml) was stirred for 20 hours at 80°C, poured out into water and extracted with diethylether. The organic layer was dried over $MgSO_4$, filtered and the solvent was evaporated. The residue (1.5 g) was purified by column chromatography over silica gel (eluent: cyclohexane/AcOEt: 97/3). The pure fractions were collected and the solvent was evaporated. Yield : 0.7 g of intermediate 23 (47 %).

Example A9

a. Preparation of intermediate 24



CDI (0.038 mol) was added at 5°C to a solution of 3-(1-naphthyl)-propionic acid (0.025 mol) in CH_2Cl_2 (60 ml). The mixture was stirred at 5°C for 1 hour. *N*-methoxymethanamine .HCl (0.038 mol) was added. The mixture was stirred at room temperature overnight. HCl 1N was added. The mixture was extracted with CH_2Cl_2. The organic layer was washed with K_2CO_3 10 %, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2 100). The pure fractions were collected and the solvent was evaporated. Yield: 5.4 g of intermediate 24 (94 %).

b. Preparation of intermediate 25



CH_3MgCl (0.025 mol) was added dropwise at 5°C to a solution of intermediate 24 (0.021 mol) in THF (51 ml). The mixture was stirred at 5°C for 2 hours, then brought to room temperature. A solution of NH_4Cl was added. The mixture was extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. Yield: 3.7 g of intermediate 25 (89 %).

c. Preparation of intermediate 26



A mixture of intermediate 25 (0.019 mol), formaldehyde (0.076 mol) and *N*-methylmethanamine (0.076 mol) in concentrated HCl (0.8 ml) and EtOH (23 ml) was stirred and refluxed for 24 hours, then cooled to room temperature. EtOH was evaporated. The residue was taken up in EtOAc. The mixture was basified with $NaHCO_3$ and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue was purified by column flash chromatography over silica gel (eluent : CH_2Cl_2/CH_3OH 97/3; 15-40 µm). Two fractions were collected and the solvent was evaporated. The desired fraction yielded 1.17 g of intermediate 26.

Intermediate 27  was prepared in the same way as intermediate 26. Yield: 18 % of intermediate 27 (oil).

Example A10

a. Preparation of intermediate 28



Formic acid (31.5 ml, 0.834 mol) was added dropwise to DMF (100 ml) under stirring and cooling with ice-cold water. Triethylamine (50.8 ml, 0.361 mol) was added in the same way followed by Meldrum's acid (40 g, 0.278 mol). After dissolution cuminaldehyde (0.278 mol) was added. The mixture was heated up to 80°C for 14 hours, then cooled down and poured out into 1 liter of ice-cold water under vigorous stirring. Concentrated HCl was added till pH 1-2. The precipitate was filtered off, washed with water and air-dried. Yield: 99% of intermediate 28.

b. Preparation of intermediate 29



1,1'-carbonyldiimidazole (6.6 g, 0.041 mol) was added portionwise to a mixture of intermediate 28 (0.027 mol) in CH_2Cl_2 (50 ml) cooled in a ice bath at 5°C. The mixture was stirred 1 hour at 5°C and N-methoxymethanamine hydrochloride (4 g, 0.041 mol) was added and the suspension was stirred at room temperature for 20 hours. The mixture was poured out into HCl 1N and extracted with CH_2Cl_2. The organic layer was washed with K_2CO_3 10%, dried over magnesium sulfate, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2: 100). The pure fractions were collected and the solvent was evaporated. Yield: 93% of intermediate 29 (93 %).

c. Preparation of intermediate 30



Methyl magnesium chloride (22 % in THF, 8.1 ml, 0.023 mol) was added slowly at 0°C under N_2 flow to a solution of intermediate 29 (0.019 mol) in THF (45 ml). The mixture was stirred at 0°C for 2 hours and hydrolyzed at 0°C with NH_4Cl 10%, and extracted with EtOAc. The organic layer was dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was used without further purification. Yield: 83% of intermediate 30 (83 %).

d. Preparation of intermediate 31



A mixture of intermediate 30 (0.019 mol), paraformaldehyde (2.3 g, 0.076 mol), dimethylamine hydrochloride (6.2 g, 0.076 mol) and hydrochloric acid concentrated (0.8 ml) in EtOH (23 ml) was stirred at reflux for 24 hours, then cooled down, and the solvent was evaporated. The residue was poured out into CH_2Cl_2, basified with $NaHCO_3$, and extracted with CH_2Cl_2. The organic layer was dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2/MeOH : 97/3).The pure fractions of the two isomers were collected and the solvent was evaporated. Yield : 10 % of intermediate 31 (10 %).

Example A11

a. Preparation of intermediate 32



A solution of NaOH 1% (50 ml) was added portionwise to a mixture of 4-fluorobenzaldehyde (21.6 ml, 0.2 mol) and acetone (40 ml, 0.55 mol) in water (40 ml). The mixture was stirred for 2 hours at 65°C, then the mixture was poured out into ice water and extracted with ethyl acetate. The organic layer was washed with brine, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was used without further purification in the next step as an oil. Yield: 34 g of intermediate 32 (100 %).

b. Preparation of intermediate 33



A mixture of intermediate 32 (4 g, 0.0244 mol), paraformaldehyde (1.1 g, 0.0365 mol), piperidine hydrochloride (0.0244 mol) and hydrochloric acid concentrated (0.8 ml) in EtOH (6 ml) was stirred at reflux for 24 hours, cooled, and the solvent was evaporated. The precipitate was filtered off, washed with EtOH and dried under vacuum at 60°C to afford intermediate 33 (63 %).

c. Preparation of intermediate 34



A mixture of intermediate 33 (7.34 mmol), palladium on activated carbon 10% (0.22 g) in EtOH/H_2O (22 ml, 50/50) was stirred under hydrogen atmosphere at room temperature for 2 hours. The mixture was filtered over celite, washed with EtOH, and the solvent was evaporated. The residue was treated by a solution of NaOH 1N in Et_2O. The organic layer was separated, and washed with brine, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was used without further purification in the next step as an oil. Yield: 76% of intermediate 34.

Example A12

a. Preparation of intermediate 35



A mixture of intermediate 32 (4.8 g, 0.0292 mol), paraformaldehyde (1.32 g, 0.0439 mol), *N*-benzylmethylamine hydrochloride (4.6 g, 0.0292 mol) and hydrochloric acid concentrated (0.8 ml) in EtOH (100 ml) was stirred at reflux for 18 hours, cooled, and the solvent was evaporated. The precipitate was filtered off, washed with acetone and dried under vacuum at 60°C. Yield: 3.8 g of intermediate 35 (39 %).

b. Preparation of intermediate 36



A mixture of intermediate 35 (3.8 g, 0.0114 mol), palladium on activated carbon 10% (0.38 g) in EtOH/H_2O (38 ml, 50/50) was stirred under hydrogen atmosphere at room temperature for 2 hours. The mixture was filtered over celite, washed with EtOH, and the solvent was evaporated. The residue was treated by a solution of NaOH 1N in Et_2O. The organic layer was separated, and washed with brine, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue (2.5 g) was purified by column chromatography over silica gel (eluent: CH_2Cl_2/CH_3OH; 99/1; 15-40 μm). The pure fraction was collected and the solvent was evaporated. Yield: 0.75 g of intermediate 36 (22 %).

Example A13

a. Preparation of intermediate 37



A mixture of intermediate 35 (2.3 g, 0.00689 mol), palladium on activated carbon 10 % (0.23 g) in EtOH/H_2O (24 ml, 50/50) was stirred under hydrogen atmosphere at room temperature for 3 hours. The mixture was filtered over celite, washed with EtOH, and the solvent was evaporated. The residue was treated by a solution of NaOH 1N in Et_2O. The organic layer was separated, and washed with brine, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was used without further purification in the next step as oil. Yield: 1.3 g of intermediate 37 (90 %).

Example A14

a. Preparation of intermediate 38



NaH (60 % in oil; 0.0072 mol) was added portionwise at 0 °C to a solution of 2-(2-ethoxyethoxy)-ethanol (0.0072 mol) in THF (12.5 ml) under N_2 flow. The mixture was stirred at 0°C for 1 hour. A solution of intermediate 10 (0.006 mol) in THF (12.5 ml) was added dropwise. The mixture was stirred and refluxed for 18 hours and was then cooled to room temperature. EtOAc and H_2O were added. The organic layer was washed with H_2O and then with saturated NaCl. The separated organic layer was dried ($MgSO_4$), filtered and the solvent was evaporated. Yield: 2.5 g intermediate 38 (97 %).

Example A15

Preparation of intermediate 39



Intermediate 39 (dia A)

nBuLi 1.6M in hexane (0.0018 mol) was added dropwise at –70°C to a solution of compound 14 (0.0007 mol) in THF (4ml) under N_2- flow. The mixture was stirred for 2 hours. *N,N*-dimethylformamide (0.0037 mol) was added slowly. The mixture was stirred at –70°C for 2 hours, poured out into H_2O and extracted with EtOAc. The organic layer was washed with saturated NaCl, dried ($MgSO_4$), filtered and the solvent was evaporated. Yield: 0.38 g of intermediate 39 (100%).

B. Preparation of the final compounds

Example B1

a. Preparation of compounds 1 and 2



compound 1 (dia A)



compound 2 (dia B)

*n*BuLi 1.6M (0.0084 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0084 mol) in THF (24 ml). The mixture was stirred at –20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 2 (prepared according to A1.b) (0.0076 mol) in THF (20 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.0107 mol) in THF (22 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out into –30°C and extracted with

CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (4.3 g) was purified by column chromatography over silica gel (eluent : $CH_2Cl_2/CH_3OH/NH_4OH$ 97/3/0.2; 15-40 µm). The pure fractions were collected and the solvent was evaporated. The residue was purified twice by column chromatography over kromasil (eluent: CH_3CN/NH_4HCO_3 0.5 % 85/15; 10 µm). Three fractions were collected and the solvent was evaporated. Yield: 0.155 g of fraction 1; 0.08 g of fraction 2 and 0.1 g of fraction 3. Fraction 1 and fraction 3 were crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.14 g of final compound 1 (8 %) (diastereoisomer A; melting point: 142°C) and 0.102 g of final compound 2 (6 %) (diastereoisomer B; melting point: 159°C).

b-1. Preparation of compounds 3 and 4



compound 3 (dia A)



compound 4 (dia B)

*n*BuLi 1.6M (0.0095 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0095 mol) in THF (26 ml). The mixture was stirred at –20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 4 (prepared according to A2.b) (0.0086 mol) in THF (24 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.012 mol) in THF (25 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out on ice at –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (5.2 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 97/3/0.1; 15-40µm). The pure fractions were collected and the solvent was evaporated. The residue (0.2 g) was purified by column chromatography over kromasil (eluent: cyclohexane/*i*PrOH/NH_4OH 95/5/0.3; 10 µm). The desired fractions were collected and the solvent was evaporated. Yield: 0.035 g of final compound 3 (3 %) (diastereoisomer A) and 0.03 g of final compound 4 (2.8 %) (diastereoisomer B).

b-2. Preparation of compounds 3 and 4



compound 3 (dia A)



compound 4 (dia B)

*n*BuLi 1.6M (0.0118 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0118 mol) in THF (30 ml). The mixture was stirred at -20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 4 (prepared according to A2.b) (0.0107 mol) in THF (35 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.015 mol) in THF (30 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out on ice at –30°C and extracted with EtOAc. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 97/3/0.1 then CH_2Cl_2/iPrOH/NH_4OH 95/5/0.4; 15-40 µm). Two fractions were collected and the solvent was evaporated. Yield: 0.13 g of fraction 1 and 0.12 g of fraction 2. Fraction 1 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.063 g of final compound 3 (diastereoisomer A). Fraction 2 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.066 g of final compound 4 (diastereoisomer B).

c. Preparation of compounds 5 and 6



compound 5 (dia A)



compound 6 (dia B)

*n*BuLi 1.6M (0.0084 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0084 mol) in THF (24 ml). The mixture was stirred at -20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 8 (prepared

according to A3.c) (0.0076 mol) in THF (25 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.0107 mol) in THF (22 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out on ice at –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (5.1 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 97/3/0.1 then toluene/*i*PrOH/NH_4OH 95/5/0.1; 15-40 µm). Three fractions were collected and the solvent was evaporated. Yield: 0.87 g of fraction 1; 0.7 g of fraction 2 and 0.4 g of fraction 3. Fraction 3 was purified by column chromatography over kromasil (eluent: toluene/*i*PrOH/NH_4OH 99/1/0.05; 10µm). Two fractions were collected and the solvent was evaporated. Yield: 0.15 g of fraction A and 0.139 g of fraction B. Fraction B was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.585 g of final compound 5 (30 %) (diastereoisomer A; melting point: 156°C). Fraction A was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.15 g of final compound 6 (8 %) (diastereoisomer B; melting point: 126°C).

d. Preparation of compounds 7 and 8



compound 7 (dia A)



compound 8 (dia B)

A solution of intermediate 11 (prepared according to A4.c) (0.0035 mol) in THF (12 ml) was added dropwise at –70°C to a solution of *N*-(1-methylethyl)-2-propanamine lithium salt (0.0038 mol) in THF (19 ml). The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of intermediate 26 (prepared according to A9.c) (0.0046 mol) in THF (12 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out into –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue (2.2 g) was purified twice by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.1; 15-40 µm). Three fractions were collected and the solvent was evaporated. Yield: 0.3 g of fraction 1 (dia A), 0.027 g of fraction 2 and 0.242 g of fraction 3 (dia B). Fraction 1 was crystallized from DIPE. The precipitate

was filtered off and dried. Yield: 0.26 g of final compound 7 (25 %) (diastereoisomer A; melting point: 206°C). Fraction 3 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.128 g of final compound 8 (12 %) (diastereoisomer B; melting point: 160°C).

e. Preparation of compound 9



compound 9 (dia A)

*n*BuLi (0.0084 mol) was added at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0084 mol) in THF (25 ml). The mixture was stirred at –20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 22 (prepared according to A7b) (0.0076 mol) in THF (26 ml) was added. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.0107 mol) in THF (24 ml) was added. The mixture was stirred at –70°C for 3 hours, poured out on ice at –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.1; 15-40 µm) then purified by column chromatography over kromasil (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 99/1/0.05). Three fractions were collected and the solvent was evaporated. Yield: 0.44 g of fraction 1 (dia A), 0.257 g of fraction 2 and 0.02 g of fraction 3. Fraction 1 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.14 g of final compound 9 (melting point: 172°C).

f. Preparation of compounds 10 and 11



compound 10 (dia A)



compound 11 (dia B)

*n*BuLi 1.6M(0.0084 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0084 mol) in THF (24 ml). The mixture was stirred at –20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 16 (prepared according to A6A.b) (0.0076 mol) in THF (26 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.0107 mol) in THF (22 ml) was added. The mixture was stirred at –70°C for 3 hours, then poured out on ice at –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (4.8 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.1; 15-40 µm). Two fractions were collected and the solvent was evaporated. Yield: 0.52 g of fraction 1 and 0.42 g of fraction 2. Both fractions were crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.47 g of final compound 10 (23 %) (diastereoisomer A; melting point: 191°C) and 0.27 g of final compound 11 (7 %) (diastereoisomer B; melting point: 179°C).

g. Preparation of compounds 17, 18, 19 and 20



compound 17 (A1)



compound 18 (A2)



compound 19 (B1)



compound 20 (B2)

*n*BuLi 1.6 M (0.0114 mol) was added dropwise at –20°C to a solution of *N*-(1-methylethyl)-2-propanamine (0.0114 mol) in THF (32 ml). The mixture was stirred at –20°C for 20 minutes, then cooled to –70°C. A solution of intermediate 11 (prepared according to A4.c) (0.0104 mol) in THF (34 ml) was added. The mixture was stirred for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (0.0146 mol) in THF (30 ml) was added. The mixture was stirred at –70°C for 3 hours, then poured out into –30°C and extracted with CH_2Cl_2. The organic layer was separated, dried ($MgSO_4$), filtered, and the solvent was evaporated. The residue (5.3 g) was purified twice by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.1; 15-40 μm). Two fractions were collected and the solvent was evaporated. Yield : 0.45g F1 and 0.22g F2. Both fractions were crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.154g F3 (dia A) and 0.11g F4 (dia B). F3 was divided into two enantiomers by Chiral PAK AD (eluent: EtOH 100; 20 μm). Two fractions were collected and the solvent was evaporated. Each fraction was crystallized separately from DIPE/diethyl ether. The precipitate was filtered off and dried. Yield: 0.19 g of compound 17 (A1) and 0.175 g of compound 18 (A2). F4 was divided into two enantiomers by Chiral PAK AD (eluent: EtOH/iPrOH 90/10; 20 μm). Two fractions were collected and the solvent was evaporated. Each fraction was crystallized separately from DIPE/diethyl ether. The precipitate was

filtered off and dried. Yield: 0.1 g of compound 19 (B1) and 0.1 g of compound 20 (B2).

h. Preparation of compounds 21 and 22



Compound 21 (dia A)



Compound 22 (dia B)

nBuLi 1.6 M in hexane (3.4 ml, 0.0055 mol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (0.78 ml, 0.0055 mol) in THF (8.5 ml). The mixture was stirred at –20°C for 20 minutes, then cooled at –70°C. A solution of 3-(4-chloro-benzyl)-6-bromo-2-methoxy-quinoline (1.67 g, 0.0046 mol) in THF (34 ml) was added slowly. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-(4-methoxy-phenyl)-pentan-3-one (1.13 g, 0.0055 mol) in THF (30 ml) was added slowly. The mixture was stirred at –70°C for 2 hours, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$; 97/3/0.1; 15-40 μm). One fraction was collected and the solvent was evaporated. This fraction was purified by Super Critical Fluid Chromatography (SCF) (CO_2/MeOH/2-propanol: 95/5/0.5, column cyano). Two fractions were collected and the solvent was evaporated. Fractions were separately crystallized from diisopropylether. Yield: 0.220 g of final compound 21 (8 %) (diastereoisomer A; melting point: 142°C) as a white solid and 0.09 g of final compound 22 (3.3 %) (diastereoisomer B; melting point: 160°C) as a white solid.

i. Preparation of compounds 23 and 24



Compound 23 (dia A)



Compound 24 (dia B)

nBuLi 1.6 M in hexane (3.4 ml, 0.0055 mol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (0.78 ml, 0.0055 mol) in THF (8.5 ml). The mixture was stirred at –20°C for 20 minutes, then cooled at –70°C. A solution of intermediate 31 (0.0046 mol) in THF (34 ml) was added slowly. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of intermediate 24 (0.0055 mol) in THF (30 ml) was added slowly. The mixture was stirred at –70°C for 2 hours, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$; 97/3/0.1; 15-40 μm). One fraction was collected and the solvent was evaporated. This fraction was purified by SFC (CO_2/MeOH/2-propanol: 95/5/0.5, column cyano). Two fractions were collected and the solvent was evaporated. Fractions were separately crystallized from diisopropylether. Yield: Final compound 23 (5 %) (diastereoisomer A) as a white foam and final compound 24 (2.3 %) (diastereoisomer B) as a white foam.

j. Preparation of compounds 29 and 30



Compound 29 (dia A)



Compound 30 (dia B)

Compounds 29 and 30 were prepared according to the procedure for compounds14 and 15, but starting from intermediate 18 and 1-(dimethylamino)-5-phenyl-3-pentanone (prepared in the same way as described in J.Am.Chem.Soc., 1950, 72, 718-721). Yield: Final compound 29 (4 %) (diastereoisomer A, melting point: 180°C) and final compound 30 (5 %) (diastereoisomer B, melting point: 120°C).

k. Preparation of compounds 31 and 32



Compound 31 (dia A)



Compound 32 (dia B)

Compounds 31 and 32 were prepared in the same way as compounds 21 and 22, but starting from intermediate 19 and 1-(dimethylamino)-5-phenyl-3-pentanone (prepared in the same way as described in J.Am.Chem.Soc., 1950, 72, 718-721).
Yield: Final compound 31 (9 %) (diastereoisomer A) and final compound 32 (diastereoisomer B, melting point: 222°C).

l. Preparation of compounds 34 and 35



Compound 34 (dia A)



Compound 35 (dia B)

nBuLi 1.6M in hexane (2.3 ml, 3.66 mmol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (0.513 ml, 3.66 mmol) in THF (8 ml). The mixture was stirred at –20°C for 20 minutes, and then cooled at –70°C. A solution of intermediate 11 (1.0 g, 3.05 mmol) in THF (10 ml) was added slowly. The mixture was stirred at –70°C for 1 hour. A solution of intermediate 34 (0.96 g, 3.66 mmol) in THF (10 ml) was added slowly. The mixture was stirred at –70°C for 1 hour, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$; 99/1/0.05; 15-40 μm). Two fractions were collected and the solvent was evaporated. The fractions were separately crystallized from methanol. Yield: 0.15 g of final compound 34 (8 %) (diastereoisomer A, melting point: 194°C) as a white solid and 0.13 g of final compound 35 (7 %) (diastereoisomer B, melting point: 170°C) as a white solid.

m. Preparation of compounds 39 and 40



Compound 39 (dia A)



Compound 40 (dia B)

nBuLi 1.6M in hexane (8.1 ml, 0.013 mol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (1.83 ml, 0.013 mol) in THF (30 ml). The mixture was stirred at –20°C for 20 minutes, and then cooled at –70°C. A solution of intermediate 11 (4.1 g, 0.0124 mol) in THF (40 ml) was added slowly. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of intermediate 37 (1.3 g, 0.00662 mol) in THF (13 ml) was added slowly. The mixture was stirred at –70°C for 1 hour, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue (5.7 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$; 94/6/0.1; 15-40 µm). Two fractions were collected and the solvent was evaporated. The fractions were separately crystallized from DIPE. Yield: 0.106 g of final compound 39 (2 %) (diastereoisomer A, melting point: 140°C) as a white solid and 0.068 g of final compound 40 (1 %) (diastereoisomer B, melting point: 250°C) as a white solid.

n. Preparation of compounds 41 and 42



Compound 41 (dia A)



Compound 42 (dia B)

nBuLi 1.6M in hexane (3 ml, 0.0048 mol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (0.67 ml, 0.0048 mol) in THF (14 ml). The mixture was stirred at –20°C for 20 minutes, then cooled at –70°C. A solution of intermediate 11 (1.44 g, 0.0044 mol) in THF (15 ml) was added slowly. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of intermediate 27 (1.5 g, 0.0062 mol) in THF (15 ml) was added slowly. The mixture was stirred at –70°C for 3 hours, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue (3.2 g) was purified by column chromatography over C18 (eluent: CH_3OH/NH_4HCO_3: 95/5; Kromasil C18, 10 µm). Two fractions were collected and the solvent was evaporated. The fractions were crystallized separately from diisopropyether and

diethylether. Yield: 0.045g of final compound 41 (3 %) (diastereoisomer A, melting point: 112°C) as a white solid and 0.2 g of final compound 42 (12 %) (diastereoisomer B, melting point: 124°C) as a white solid.

o. Preparation of compounds 43 and 44



Compound 43 (dia A)



Compound 44 (dia B)

nBuLi 1.6M in hexane (4.1 ml, 0.0066 mol) was added dropwise at –20°C under N_2 flow to a solution of diisopropylamine (0.93 ml, 0.0066 mol) in THF (12 ml). The mixture was stirred at –20°C for 20 minutes, then cooled at –70°C. A solution of intermediate 38 (2.6 g, 0.0060 mol) in THF (27 ml) was added. The mixture was stirred at –70°C for 1 hour and 30 minutes. A solution of 1-(dimethylamino)-5-phenyl-3-pentanone (prepared in the same way as described in J.Am.Chem.Soc., 1950, 72, 718-721) (1.7 g, 0.0084 mol) in THF (20 ml) was added. The mixture was stirred at –70°C for 3 hours, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue (2.5 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$: 97/3/0.1; 15-40 µm). Two fractions were collected and the solvent was evaporated. Yield: 0.15 g fraction 1 and 0.22 g fraction 2. Fraction 1 was crystallized from DIPE/diethyl ether. The precipitate was filtered off and dried. Yield: 0.129 of final compound 43 (3.4 %) (diastereoisomer A, melting point: 94°C) Fraction 2 was repurified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$: 97/3/0.1; 15-40 µm) and crystallized from DIPE/diethyl ether. The precipitate was filtered off and dried. 0.059 g of final compound 44 (2 %) (diastereoisomer B, melting point: 103°C).

Example B2

a. Preparation of compound 12



compound 12 (dia A)

A mixture of final compound 5 (prepared according to B1.c) (0.282 mol) and $HCOONH_4$ (1.41 mol) in Pd/C (0.15 ml) and CH_3OH (3 ml) was stirred and refluxed for 30 minutes, then cooled to room temperature, filtered over celite and washed with CH_2Cl_2. The filtrate was washed with H_2O, then with saturated NaCl. The organic layer was separated, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.11 g of final compound 12 (86 %) (melting point: 122°C).

b. Preparation of compound 36



Compound 36 (dia B)

A solution of final compound compound 15 (0.25 g, 0.00047 mol), pyridine-3-boronic acid (0.116 g, 0.00094 mol) and tetrakis (triphenylphosphine) palladium(0) (0.054 g, 0.000047 mol) in ethyleneglycol dimethyl ether (13 ml) and a solution of sodium carbonate 2M (0.94 ml) was stirred overnight at 80°C. Then the solution was cooled to room temperature, poured out into water and extracted with CH_2Cl_2. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue (0.3 g) was purified by column chromatography over silica gel (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$; from 99/1/0.1 to 94/6/0.6; 15-30 μm). The pure fraction was collected and the solvent was evaporated. Yield: 0.024 g of final compound 36 (9.6 %).

Example B3

a. Preparation of compounds 25, 26, 27 and 28



Compound 25 (A1)



Compound 26 (A2)



Compound 27 (B1)



Compound 28 (B2)

To obtain the corresponding enantiomers, 0.416 g of final compound 49 (diastereoisomer A) was purified by SFC chiral chromatography (ChiralPakADH 250x21mm, eluent: CO_2/EtOH/2-propanol: 85/15/0.3). Two fractions were collected and the solvent was evaporated, to yield 0.13 g of final compound 25 (enantiomer A1) as a white solid and 0.13 g of final compound 26 (enantiomer A2).

To obtain the corresponding enantiomers, 0.655 g of final compound 50 (diastereoisomer B) was purified by SFC chiral chromatography (ChiralPakADH 250x21mm, eluent: CO_2/EtOH/2-propanol:85/15/0.3). Two fractions were collected and the solvent was evaporated, to yield 0.105 g of final compound 27 (enantiomer B1) as a white solid and 0.1 g of final compound 28 (enantiomer B2).

Example B4

a. Preparation of compound 33



Compound 33 (dia A)

Final compound 33 was prepared in the same way as compound 21 starting from intermediate 23 and 1-(dimethylamino)-5-phenyl-3-pentanone (prepared in the same way as described in J.Am.Chem.Soc., 1950, 72, 718-721). Yield: 5% of final compound 33 (diastereoisomer A).

Example B5

a. Preparation of compound 92



nBuLi 1.6M in hexane (2.5 ml, 0.004 mol) was added slowly at –20°C under N_2 flow to a solution of diisopropylamine (0.562 ml, 0.004 mol) in THF (9 ml). The mixture was stirred at –20°C for 20 minutes, then cooled at –70°C. A solution of intermediate 11 (1.1 g, 0.00334 mol) in THF (11 ml) was added slowly. The mixture was stirred at –70°C for 1 hour. A solution of intermediate 36 (1.0 g, 0.00334 mol) in THF (10 ml) was added slowly. The mixture was stirred at –70°C for 1 hour, hydrolyzed at –30°C with ice water, and extracted with EtOAc. The organic layer was separated, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc; 83/17; 15-40 μm). The

pure fraction was collected and the solvent was evaporated. Yield: 0.75 g of intermediate 36 (mixture of diastereoisomers) (36 %).

b. Preparation of compounds 37 and 38



Compound 37 (dia A)



Compound 38 (dia B)

A mixture of final compound 92 (0.45 g, 0.72 mmol) in CH_2Cl_2 (2 ml), ammonium formate (0.23 g, 0.0036 mol), palladium on activated carbon 10 % (0.45 g) in methanol (9 ml) was stirred for 30 minutes at 80°C. Then the mixture was poured out into ice water and extracted with ethyl acetate. The organic layer was washed with brine, dried over $MgSO_4$, filtered, and the solvent was evaporated. The residue (0.45 g) was purified by column chromatography over silica gel (eluent: toluene/2-propanol/ NH_4OH; 90/10/0.5; 15-40 μm). Two fractions were collected and the solvent was evaporated. The fractions were separately crystallized from DIPE. Yield: 0.102 g of final compound 37 (30 %) (diastereoisomer A, melting point: 134°C) as a white solid and 0.064 g of final compound 38 (20 %) (diastereoisomer B, melting point: 138°C) as a white solid.

Example B6

Preparation of compound 58



compound 58 (dia A)

$NaBH_4$ (0.0007 mol) was added at 0°C to a solution of intermediate 39 (0.0007 mol) (prepared according to Example A15) in MeOH (6 ml) and THF (6ml). The mixture was stirred at 0°C for 2 hours, poured out into H_2O and extracted with EtOAc. The organic layer was washed with saturated NaCl, dried ($MgSO_4$), filtered and the solvent was evaporated. The residue (0.7 g) was purified by column chromatography over kromasil (eluent: $CH_2Cl_2/CH_3OH/NH_4OH$ 98/2/0.2; 3.5 μm). The pure fractions were collected and the solvent was evaporated. This fraction was crystallized from DIPE/diethyl ether. The precipitate was filtered off and dried. Yield: 0.05 g of compound 58 (dia A).

Tables 1 to 5 below list compounds which were prepared according to one of the above Examples (Ex. No.)

Table 1:



Comp. nr.	Ex. nr.	R^1_a	R^1_b	R^1_c	R^3	X	melting points and stereochemistry
12	B2.a	H	H	H	phenyl	O	(A); 122°C
13	B2.a	H	H	H	phenyl	O	(B); 162°C
1	B1.a	H	CH_3	H	phenyl	O	(A); 142°C
2	B1.a	H	CH_3	H	phenyl	O	(B); 159°C
3	B1.b	H	OCH_3	H	phenyl	O	(A)
4	B1.b	H	OCH_3	H	phenyl	O	(B)
14	*	H	Br	H	phenyl	O	(A); 178°C
15	*	H	Br	H	phenyl	O	(B); 146°C
17	B1g	H	Br	H	phenyl	O	(A1)
18	B1g	H	Br	H	phenyl	O	(A2)
19	B1g	H	Br	H	phenyl	O	(B1)
20	B1g	H	Br	H	phenyl	O	(B2)
10	B1.f	H	Br	H	phenyl	S	(A); 191°C
11	B1.f	H	Br	H	phenyl	S	(B); 179°C
7	B1.d	H	Br	H	1-naphthyl	O	(A); 206°C
8	B1.d	H	Br	H	1-naphthyl	O	(B); 160°C
16	B1.f	H	Br	CH_3	phenyl	O	(A); 168°C
9	B1.e	H	Cl	H	phenyl	O	(A); 172°C
5	B1.c	Br	H	H	phenyl	O	(A); 156°C
6	B1.c	Br	H	H	phenyl	O	(B); 126°C
24	B1.i	H	Br	H	4-isopropylphenyl	O	(B)
23	B1.i	H	Br	H	4-isopropylphenyl	O	(A)
45	B1.i	H	Br	H		O	(B)

Comp. nr.	Ex. nr.	R^1_a	R^1_b	R^1_c	R^3	X	melting points and stereochemistry
46	B1.i	H	Br	H		O	(B); 154°C
47	B1.i	H	Br	H	3-fluorophenyl	O	(A); 165°C
48	B1.i	H	Br	H	3-fluorophenyl	O	(B); 167°C
49	B1.i	H	Br	H	4-fluorophenyl	O	(A); 148°C
50	B1.i	H	Br	H	4-fluorophenyl	O	(B); 156°C
27	B3.a	H	Br	H	4-fluorophenyl	O	(B1)
28	B3.a	H	Br	H	4-fluorophenyl	O	(B2)
25	B3.a	H	Br	H	4-fluorophenyl	O	(A1)
26	B3.a	H	Br	H	4-fluorophenyl	O	(A2)
51	B1.i	H	Br	H	3,4-difluorophenyl	O	(B); 140°C
52	B1.i	H	Br	H	4-methylphenyl	O	(B); 154°C
53	B1.i	H	Br	H	4-methylphenyl	O	(A); 138°C
54	B1.i	H	Br	H	2-chlorophenyl	O	(B); 146°C
55	B1.i	H	Br	H	4-chlorophenyl	O	(B); 148°C
56	B1.i	H	Br	H	4-chlorophenyl	O	(A); 167°C
57	B1.i	H	Br	H	3,4-dichlorophenyl	O	(B); 164°C
58	B6	H	$HOCH_2$--	H	phenyl	O	(A)
29	B1.j	H	CH_3	H	phenyl	S	(A); 180°C
30	B1.j	H	CH_3	H	phenyl	S	(B); 120°C
59	B2.b	H	phenyl	H	phenyl	O	(B)
60	B2.b	H	phenyl	H	phenyl	O	(A)
61	B2.b	H		H	phenyl	O	(A)
36	B2.b	H		H	phenyl	O	(B)
62	B2.b	H		H	phenyl	O	(B); 128°C
63	B2.b	H		H	phenyl	O	(A)
64	B2.b	H		H	phenyl	O	(B)

* prepared as described in WO 2004/01146

Table 2:



Comp. nr.	Ex. nr.	$R^1{}_b$	R^3	melting points and stereochemistry
37	B5.a	H	4-fluorophenyl	(A); 134°C
38	B5.a	H	4-fluorophenyl	(B); 138°C
39	B1.m	Br	4-fluorophenyl	(A); 250°C
40	B1.m	Br	4-fluorophenyl	(B); 140°C

Table 3:



Comp. nr.	Ex. nr.	R^2	R^3	$R^6{}_b$	$R^6{}_c$	melting points and stereochemistry
65	B1.h	OCH_3	phenyl	H	CH_3	(A)
66	B1.h	OCH_3	phenyl	H	CH_3	(B); 149°C
67	B1.h	OCH_3	phenyl	Cl	H	(A); 166°C
68	B1.h	OCH_3	phenyl	Cl	H	(B); 154°C
69	B1.h	OCH_3	phenyl	H	Cl	(A)
70	B1.h	OCH_3	phenyl	H	Cl	(B); 162°C
71	B1.h	OCH_3	phenyl	CH_3	H	(A); 158°C
72	B1.h	OCH_3	phenyl	CH_3	H	(B)
73	B1.h	OCH_3	phenyl	H	OCH_3	(A)
74	B1.h	OCH_3	phenyl	H	OCH_3	(B); 151°C
75	B1.h	OCH_3	4-chlorophenyl	H	Cl	(A); 190°C

Comp. nr.	Ex. nr.	R^2	R^3	$R^6{}_b$	$R^6{}_c$	melting points and stereochemistry
76	B1.h	OCH_3	4-chlorophenyl	H	Cl	(B); 174°C
77	B1.h	OCH_3	3-fluorophenyl	H	Cl	(A); 174°C
78	B1.h	OCH_3	3-fluorophenyl	H	Cl	(B); 172°C
79	B1.h	OCH_3	4-fluorophenyl	H	Cl	(A)
80	B1.h	OCH_3	4-fluorophenyl	Cl	H	(A); 169°C
81	B1.h	OCH_3	4-fluorophenyl	Cl	H	(B); 158°C
82	B1.h	OCH_3	4-fluorophenyl	CH_3	H	(A); 138°C
83	B1.h	OCH_3	4-fluorophenyl	CH_3	H	(B); 144°C
84	B1.h	OCH_3	4-fluorophenyl	H	OCH_3	(A); 156°C
85	B1.h	OCH_3	4-fluorophenyl	H	OCH_3	(B); 172°C
86	B1.h	OCH_3	4-methylphenyl	H	Cl	(A)
87	B1.h	OCH_3	4-methylphenyl	H	Cl	(B); 180°C
88	B1.h	OCH_3	2-methoxyphenyl	H	Cl	(B)
22	B1.h	OCH_3	4-methoxyphenyl	H	Cl	(B); 160°C
21	B1.h	OCH_3	4-methoxyphenyl	H	Cl	(A); 142°C
89	B1.h	OCH_3		H	Cl	(B); 140°C
90	B1.h	OCH_3		H	Cl	(A); 161°C
91	B1.h	OCH_3		H	Cl	(B)
43	B1.o	2-(2-ethoxy-ethoxy)ethoxy	phenyl	H	H	(A); 94°C
44	B1.o	2-(2-ethoxy-ethoxy)ethoxy	phenyl	H	H	(B); 103°C
31	B1.k	SCH_3	phenyl	H	Cl	(A)
32	B1.k	SCH_3	phenyl	H	Cl	(B); 222°C
33	B4.a	$N(CH_3)_2$	phenyl	H	Cl	(A)

Table 4:



Comp. nr.	Ex. nr.	R^3	Y	melting points and stereochemistry
34	B1.l	4-fluorophenyl		(A); 140°C
35	B1.l	4-fluorophenyl		(B); 179°C
92	B5.a	4-fluorophenyl	-N(CH_3)(CH_2-C_6H_5)	

Table 5:



Comp. nr.	Ex. nr.	melting points and stereochemistry
41	B1.n	(A); 112°C
42	B1.n	(B); 124°C

ANALYTICAL PART

LCMS results

General procedure

The HPLC gradient was supplied by an Alliance HT 2795 (Waters) system consisting of a quaternary pump with degasser, an autosampler, and DAD detector. Flow from the column was split to the MS detector. MS detectors were configured with an electrospray ionization source. The capillary needle voltage was 3 kV and the source temperature was maintained at 100 °C on the LCT (Time of Flight-Z-spray mass spectrometer from Waters) and 3.15 kV and 110 °C on the ZQ (simple quadripole- Z-spray mass spectrometer from Waters). Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.

Method 1

In addition to the general procedure: Reversed phase HPLC was carried out on an Kromasil C18 column (5 µm, 4.6 x 150 mm) with a flow rate of 1.0 ml/min. Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; mobile phase C: 0.2 % formic acid + 99.8 % ultra-pure Water) were employed to run a gradient condition from 30 % A , 40% B and 30% C (hold for 1 minute) to 100 % B in 4 minutes, 100% B for 5 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 5 µl was used.
Cone voltage was 20 V for positive ionization mode. Mass spectra were acquired by scanning from 100 to 900 in 0.8 seconds using an interscan delay of 0.08 seconds.

Method 2

In addition to the general procedure: Reversed phase HPLC was carried out on a Sunfire C18 column (3.5 µm, 4.6 x 100 mm) with an intial flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 25% 6.5mM ammonium acetate + 50% acetonitrile +25% formic acid (2ml/l); mobile phase B: 100% acetonitrile) were employed to run a gradient condition from 100 % A (hold for 1 minute) to 100% B in 4 minutes, hold at 100% B at a flow rate of 1.2 ml/min for 4 minutes and reequilibrated with initial conditions for 3 minutes). An injection volume of 10 µl was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

Method 3

In addition to the general procedure: Reversed phase HPLC was carried out on an Kromasil C18 column (5 µm, 4.6 x 150 mm) with a flow rate of 1.0 ml/min. Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; mobile phase C: 0.2 % formic acid + 99.8 % ultra-pure Water) were employed to run a gradient condition from 30 % A , 40% B and 30% C (hold for 1 minute) to 100 % B in 4 minutes, 100% B for 5 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 5 µl was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 900 in 0.8 seconds using an interscan delay of 0.08 seconds.

Method 4

In addition to the general procedure: Reversed phase HPLC was carried out on a Sunfire C18 column (3.5 µm, 4.6 x 100 mm) with an initial flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 35% 6.5mM ammonium acetate + 30% acetonitrile + 35% formic acid (2ml/l); mobile phase B: 100% acetonitrile) were employed to run a gradient condition from 100 % A (hold for 1 minute) to 100% B in 4 minutes, hold at 100% B at a flow rate of 1.2 ml/min for 4 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 10 µl was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.

Table 6 : LCMS results (retention time Rt (minutes) and molecular weight as the MH^+

Comp. No.	Rt	MH+	Method LCMS
3	5.34	485	1
4	5.43	485	1
17	6	533	3
18	6.04	533	3
19	6.07	533	3
20	6.06	533	3
24	5.5	575	4
23	5.43	575	4
45	5.23	617	4
27	4.98	551	4
28	4.98	551	4

Comp. No.	Rt	MH+	Method LCMS
25	4.97	551	4
26	4.97	551	4
58	4.57	485	1
59	6.5	531	1
60	6.56	531	1
61	5.13	532	1
36	4.37	532	1
63	6.38	537	1
64	6.37	537	1
65	3.55	547	2
69	4.05	567	2
72	5.15	547	4
73	5.93	563	1
79	5.23	585	4
86	5.33	581	4
88	5.23	597	4
91	5.6	651	4
31	5.42	583	4
33	5.13	580	4

Optical rotation

The optical rotation was measured using a polarimeter. $[\alpha]_D^{20}$ indicates the optical rotation measured with light at the wavelength of the D-line of sodium (589 nm) at a temperature of 20°C. Table 7 lists the obtained optical rotation values, concentration and solvent used to measure the optical rotation.

Table 7

Comp. No.	$[\alpha]_D^{20}$	concentration	solvent
17	+141.82°	0.483 w/v %	DMF
18	-140.28°	0.494 w/v %	DMF
19	+154.08°	0.392 w/v %	DMF
20	-139.21°	0.4195 w/v %	DMF
27	+135.71°	0.532 w/v %	DMF
26	-143.38°	0.521 w/v %	DMF

Comp. No.	$[\alpha]_D^{20}$	concentration	solvent
25	+142.91°	0.536 w/v %	DMF
28	-141.23°	0.519 w/v %	DMF

Pharmacological examples

Preparation of bacterial suspensions for susceptibility testing:

The bacteria used in this study were grown overnight in flasks containing 100 ml Mueller-Hinton Broth (Becton Dickinson - cat. no. 275730) in sterile de-ionized water, with shaking, at 37 °C. Stocks (0.5 ml/tube) were stored at –70 °C until use. Bacteria titrations were performed in microtiter plates and colony forming units (CFUs) were determined. In general, an inoculum level of approximately 100 CFUs was used for susceptibility testing.

Anti bacterial Susceptibility testing: IC_{90} determination

Microtitre plate assay

Flat-bottom, sterile 96-well plastic microtiter plates were filled with 180 µl of sterile deionized water, supplemented with 0.25 % BSA. Subsequently, stock solutions (7.8 x final test concentration) of compounds were added in 45 µl volumes in column 2. Serial five-fold dilutions (45 µl in 180 µl) were made directly in the microtiter plates from column 2 to reach column 11. Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate. Depending on the bacteria type, approximately 10 to 60 CFU per well of bacteria inoculum (100 TCID50), in a volume of 100 µl in 2.8x Mueller-Hinton broth medium, was added to the rows A to H, except column 12. The same volume of broth medium without inoculum was added to column 12 in row A to H. The cultures were incubated at 37°C for 24 hours under a normal atmosphere (incubator with open air valve and continuous ventilation). At the end of incubation, one day after inoculation, the bacterial growth was quantitated fluorometrically. Therefore resazurin (0.6 mg/ml) was added in a volume of 20 µl to all wells 3 hours after inoculation, and the plates were re-incubated overnight. A change in colour from blue to pink indicated the growth of bacteria. The fluorescence was read in a computer-controlled fluorometer (Cytofluor Biosearch) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm. The % growth inhibition achieved by the compounds was calculated according to standard methods. The IC_{90} (expressed in µg/ml) was defined as the 90 % inhibitory concentration for bacterial growth. The results are shown in Table 8 below.

Agar dilution method.

MIC_{99} values (the minimal concentration for obtaining 99 % inhibition of bacterial growth) can be determined by performing the standard Agar dilution method according to NCCLS standards* wherein the media used includes Mueller-Hinton agar.

* Clinical laboratory standard institute. 2005. Methods for dilution Antimicrobial susceptibility tests for bacteria that grows Aerobically: approved standard -sixth edition

Time kill assays

Bactericidal or bacteriostatic activity of the compounds may be determined in a time kill assay using the broth microdilution method *. In a time kill assay on *Staphylococcus aureus* and methicillin resistant *S. aureus* (MRSA), the starting inoculum of *S. aurues* and MRSA is 10^6 CFU / ml in Muller Hinton broth. The antibacterial compounds are used at the concentration of 0.1 to 10 times the MIC (i.e. IC_{90} as determined in microtitre plate assay). Wells receiving no antibacterial agent constitute the culture growth control. The plates containing the microorganism and the test compounds are incubated at 37 °C. After 0, 4, 24, and 48 hrs of incubation samples are removed for determination of viable counts by serial dilution (10^{-1} to 10^{-6}) in sterile PBS and plating (200 µl) on Mueller Hinton agar. The plates are incubated at 37 °C for 24 hours and the number of colonies are determined. Killing curves can be constructed by plotting the $\log_{10}$CFU per ml versus time. A bactericidal effect is commonly defined as 3-$\log_{10}$ decrease in number of CFU per ml as compared to untreated inoculum. The potential carryover effect of the drugs is removed by serial dilutions and counting the colonies at highest dilution used for plating. No carryover effect is observed at the dilution of 10^{-2} used for plating. This results in limit of detection 5 X 10^2 CFU / ml or <2.7 log CFU/ml.

* Zurenko,G.E. *et al.* In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. *Antimicrob. Agents Chemother.* **40**, 839-845 (1996).

Determination of cellular ATP levels

In order to analyse the change in the total cellular ATP concentration (using ATP bioluminescence Kit, Roche), assays are carried out by growing a culture of *S. aureus* (ATCC29213) stock in 100 ml Mueller Hinton flasks and incubate in a shaker-incubator for 24 hrs at 37 °C (300 rpm). Measure OD_{405} nm and calculate the CFU/ml. Dilute the cultures to 1 x 10^6 CFU/ml (final concentration for ATP measurement: 1 x 10^5 CFU/100 µl per well) and add test compound at 0.1 to 10 times the MIC (i.e. IC_{90} as determined in microtitre plate assay). Incubate these tubes for 0, 30 and 60 minutes

at 300 rpm and 37 °C. Use 0.6 ml bacterial suspension from the snap-cap tubes and add to a new 2 ml eppendorf tubes. Add 0.6 ml cell lysis reagent (Roche kit), vortex at max speed and incubate for 5 minutes at room temperature. Cool on ice. Let the luminometer warm up to 30°C (Luminoskan Ascent Labsystems with injector). Fill one column (= 6 wells) with 100 µl of the same sample. Add 100 µl Luciferase reagent to each well by using the injector system. Measure the luminescence for 1 sec.

Table 8 : IC_{90} values (µg/ml) determined according to the Microtitre plate assay.

	IC_{90} µg/ml										
Comp. No.	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
17							4.8			8.5	
18			10.6		10.6		2.1	8.5		8.5	
19			1.7		1.7		2.1	1.7		8.5	
20			1.7		1.7		1.1	1.7		8.5	
8			1.9	1.9	2.3		11.6	1.9		1.9	1.9
15	10.6		4.8	2.1	4.8		7.5	4.2	4.8	4.8	10.6
12							9.1			10.2	
1			37.2		18.7		1.9	7.4		9.4	
2			37.2		37.2		1.9	37.2		7.4	
3			9.7		9.7		3.4	9.7		12.2	
4							9.7			10.9	
14	13.4		9.5	10.6	9.5		42.4	10.6	11.9	13.4	13.4
6							1.7			8.5	
16			10.9		2.2		2.2	2.2		19.4	

Comp. No.	IC_{90} µg/ml										
	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
10							9.8			13.8	
11			43.7		43.7		3.9	8.7		11.0	
13							4.1			36.1	
5			53.4		53.4		4.8	42.4		23.8	
7							46.4			52.0	
9							1.7			24.5	
39							0.3			1.7	
37							0.3			2.9	
38							0.3			1.5	
55							0.3			1.8	
40							0.3			1.5	
24							0.3			2.6	
23							0.3			16.2	
91							0.3			32.7	
22			9.5		1.9		0.4	1.9		1.9	
45			2.2		0.7		0.4	2.0		2.5	
76							0.4			2.1	
31			58.4		9.3		0.4	1.9		58.4	
50	9.8		1.7	8.7	1.7		0.4	1.7		1.7	8.7

Comp. No.	IC_{90} µg/ml										
	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
69			1.8		1.8		0.5	4.0		1.8	12.7
83			9.0		4.0		0.5	1.8		1.8	
88			37.7		2.1		0.5	1.9		9.5	
46			1.9		1.9		0.5	1.9		1.9	
81			9.3		1.9		0.6	1.9		1.9	
68			56.8		11.3		0.7	56.8		2.3	
65			1.7		1.7		0.8	1.7		3.9	10.9
66			9.7		43.5		0.8	1.7		1.7	12.3
33			1.8		1.8		0.8	1.5		1.8	
77			3.7		1.9		0.8	1.9		1.9	
52			1.7		1.7		1.4	1.7		6.9	
28			3.9		3.9		0.9	3.9		1.7	
78			9.3		1.9		1.5	1.9		7.4	
71			54.8		54.8		1.7	43.5		2.2	
25							1.7			7.8	
73			8.9		8.0		1.8	4.0		7.1	
57							0.5			6.0	
74			1.8		1.8		1.8	1.8		1.8	12.6
56							5.7			9.0	

Comp. No.	IC_{90} µg/ml										
	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
70			56.8		45.1		1.8	45.1		1.8	12.7
80			8.3		1.9		1.9	3.3		9.3	
61							7.5				
36			42.2		42.2		1.7	16.8		1.7	
53			6.9		3.9		1.7	1.7		1.7	13.8
26			1.7		1.7		2.0	1.7		4.4	
27							2.0			1.7	
84			58.2		46.2		2.1	46.2		4.6	
85							2.1			4.1	
86							2.1			41.2	
32							2.1			9.3	
21			1.9		1.9		2.1	1.9		1.9	
63			19.0		8.5		2.1	21.4		10.7	
72			43.5		43.5		2.2	43.5		1.7	
48			43.8		43.8		2.2	43.8		1.7	
82			1.8		1.8		2.3	1.8		1.8	
43			10.1		10.1		2.3	10.1		10.1	
67			56.8		56.8		2.3	56.8		2.3	
89							2.3			22.6	

Comp. No.	IC_{90} µg/ml										
	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
87			11.6		9.2		2.3	5.2		9.2	
79			58.6		46.5		2.3	46.5		9.3	
90							2.6			16.4	
75							3.4			3.0	
35			59.2		59.2		3.7	9.4		59.2	
44			10.1		4.5		4.5	8.0		22.6	
58							8.6			8.6	
47							8.7			43.8	
34							9.4			59.2	
62							10.4			8.3	
60							10.6			53.1	
59							10.6			42.2	
64							10.7			42.6	
29							7.7			48.5	
30							1.9			7.7	
54			4.5		2.0		2.3	2.0		10.1	
41							2.3			57.0	
42			22.7		10.1		2.3	4.5		9.0	
51			10.1		9.0		0.4	5.7		1.8	11.4

Comp. No.	IC_{90} µg/ml										
	BSU 43639	EFA 14506	EFA 29212	LMO 49594	PAE 27853	SMU 33402	SPN 6305	SPY 8668	STA 25923	STA 29213	STA RMETH
49			43.8		43.8		2.2	43.8		11.0	

BSU 43639 means *Bacillus subtilis* (ATCC43639); EFA 14506 means *Enterococcus faecalis* (ATCC14506); EFA 29212 means *Enterococcus faecalis* (ATCC29212); LMO 49594 means *Listeria monocytogenes* (ATCC49594); PAE 27853 means *Pseudomonas aeruginosa* (ATCC27853); SMU 33402 means *Streptococcus mutans* (ATCC33402); SPN 6305 means *Streptococcus pneumoniae* (ATCC6305); SPY 8668 means *Streptococcus pyogens* (ATCC8668); STA 25923 means *Staphylococcus aureus* (ATCC25923); STA 29213 means *Staphylococcus aureus* (ATCC29213); STA RMETH means methicilline resistant *Staphylococcus aureus* (MRSA) (a clinical isolate from the University of Antwerp).
ATCC means American type tissue culture.

Claims

1. Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection, said compound being a compound of formula (Ia) or (Ib)



(Ia)



(Ib)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof, wherein

R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;

p is an integer equal to 1, 2, 3 or 4 ;

R^2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula  wherein Y is CH_2, O, S, NH or *N*-alkyl ;

R^3 is Ar or Het;

R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or

R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl,

hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl or pyrimidinyl ;

R^6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ; or

two vicinal R^6 radicals may be taken together to form a bivalent radical of formula -CH=CH-CH=CH- ;

r is an integer equal to 1, 2, 3, 4 or 5 ;

R^7 is hydrogen, alkyl, Ar or Het ;

R^8 is hydrogen or alkyl ;

R^9 is oxo ; or

R^8 and R^9 together form the radical –CH=CH-N=;

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with hydroxy, alkyloxy or oxo;

Alk is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ;

Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl and tetrahydronaphthyl, each homocycle optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

Het is a monocyclic heterocycle selected from the group of *N*-phenoxypiperidinyl, piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, hydroxy, alkyl, alkyloxy, and Ar-carbonyl;

halo is a substituent selected from the group of fluoro, chloro, bromo and iodo; and

haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein one or more carbon atoms are substituted with one or more halo atoms;

provided that the bacterial infection is other than a Mycobacterial infection.

2. Use according to claim 1 wherein R^1 is hydrogen, halo, alkyl, alkyloxy, Ar or Het.

3. Use according to claim 2 wherein R^1 is hydrogen, halo, alkyl or alkyloxy.

4. Use according to claim 3 wherein R^1 is hydrogen or halo.

5. Use according to claim 4 wherein R^1 is halo.

6. Use according to any one of the preceding claims wherein p is equal to 1.

7. Use according to claim 6 wherein the R^1 substituent is placed in position 6 of the quinoline ring.

8. Use according to any one of the preceding claims wherein R^2 is alkyloxy, alkylthio, mono-or di(alkyl)amino or alkyloxyalkyloxy.

9. Use according to any one of claims 1 to 7 wherein R^2 is hydrogen, alkyloxy or alkylthio.

10. Use according to claim 8 or 9 wherein R^2 is C_{1-4}alkyloxy.

11. Use according to any one of the preceding claims wherein R^3 is Ar.

12. Use according to claim 11 wherein R^3 is naphthyl or phenyl, optionally substituted with 1 or 2 halo.

13. Use according to any one of the preceding claims wherein R^4 and R^5 each independently are hydrogen or C_{1-4}alkyl.

14. Use according to any one of the preceding claims wherein R^6 is hydrogen.

15. Use according to any one of the preceding claims wherein R^7 is hydrogen.

16. Use according to any one of the preceding claims wherein Alk is methylene or ethylene.

17. Use according to claim 16 wherein Alk is ethylene.

18. Use according to any one of the preceding claims wherein the compound is a compound according to formula (Ia).

19. Use according to claim 1 wherein the compound is a compound of formula (Ia) wherein R^1 is hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkyloxy, Ar or Het; p = 1 or 2; R^2 is C_{1-4}alkyloxy, C_{1-4}alkylthio, mono-or di(C_{1-4}alkyl)amino, C_{1-4}alkyloxyC_{1-4}alkyloxyC_{1-4}alkyloxy; R^3 is optionally substituted naphthyl or phenyl; R^4 and R^5 each independently are hydrogen or C_{1-4}alkyl; or R^4 and R^5 together and including the N to which they are attached form a piperidinyl; R^6 is hydrogen, halo, C_{1-4}alkyl or C_{1-4}alkyloxy; r is equal to 1; R^7 is hydrogen; Alk is methylene or ethylene.

20. Use according to any one of the preceding claims wherein the bacterial infection is an infection with a gram-positive bacterium.

21. Use according to any one of the preceding claims wherein the compound is selected from





a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

22. A compound selected from



R^1_a	R^1_b	R^1_c	R^3	X
H	H	H	phenyl	O
H	CH_3	H	phenyl	O
H	OCH_3	H	phenyl	O
H	Br	H	phenyl	S
H	Br	H	1-naphthyl	O
H	Br	CH_3	phenyl	O
H	Cl	H	phenyl	O
Br	H	H	phenyl	O

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

23. A compound selected from



R^1	R^3	R^4
Br	4-fluorophenyl	H
H	4-fluorophenyl	H
Br	4-chlorophenyl	CH_3

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

24. A compound selected from



R^1	R^3	R^4	stereochemistry
Br	4-fluorophenyl	H	(A)
Br	4-fluorophenyl	H	(B)
H	4-fluorophenyl	H	(A)
H	4-fluorophenyl	H	(B)
Br	4-chlorophenyl	CH_3	(B)

a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a *N*-oxide form thereof.

25. A combination of (a) a compound of formula (Ia) or (Ib) as defined in any one of the preceding claims, and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents.

26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of (a) a compound of formula (Ia) or (Ib) as defined in any one of claims 1 to 24, and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents.

27. The use of a combination as claimed in claim 25 or a pharmaceutical composition as claimed in claim 26 for the manufacture of a medicament for the treatment of a bacterial infection.

28. A product containing (a) a compound of formula (Ia) or (Ib) as defined in any one of claims 1 to 24, and (b) one or more other antibacterial agents provided that the one or more other antibacterial agents are other than antimycobacterial agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of a bacterial infection.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/063556

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/4353 A61P31/04 C07D215/227 C07D215/36 C07D215/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/011436 A (JANSSEN PHARMACEUTICA N.V; VAN GESTEL, JOZEF, FRANS, ELISABETHA; GUILL) 5 February 2004 (2004-02-05) cited in the application	1-24
Y	claims 1,8,9; table 1; compounds 95,96	25-28
Y	HELWIG, BURGHARD: "Moderne Arzneimittel" 1980, WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT , STUTTGART , XP002359316 page 395	25-28

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 September 2006	29/09/2006

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Krische, Detlef

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/063556

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANDRIES, KOEN ET AL.: SCIENCE, vol. 307, 14 January 2005 (2005-01-14), pages 223-227, XP002358962 cited in the application page 223 - page 224	1-24
A	DESAI P K ET AL: "QUINOLINE DERIVATIVES AS ANTITUBERCULAR/ANTIBACTERIAL AGENTS" INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 35B, no. 8, August 1996 (1996-08), pages 871-873, XP000944820 the whole document	1
P,X	WO 2005/117875 A (JANSSEN PHARMACEUTICA N.V; ANDRIES, KOENRAAD, JOZEF, LODEWIJK, MARCEL;) 15 December 2005 (2005-12-15) claims 1,23,25-27; table 1; compounds 95,96 page 20, lines 11-17	25-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2006/063556

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004011436 A	05-02-2004	AU 2003262529 A1	16-02-2004
		CA 2493225 A1	05-02-2004
		CN 1671667 A	21-09-2005
		EP 1527050 A1	04-05-2005
		HR 20050045 A2	30-06-2006
		JP 2006504658 T	09-02-2006
		MX PA05001052 A	08-04-2005
		NZ 538391 A	28-10-2005
WO 2005117875 A	15-12-2005	AR 049127 A1	28-06-2006